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ABSTRACT 
Malaria is considered as one of the most prevalent and debilitating diseases affecting 
humans. Plasmodium falciparum is the most virulent form of the parasite which 
developed resistance to several antimalarial drugs. Chloroquine is one of the most 
successful antimalarials developed that is safe, effective, and cheap. However, its use has 
been limited due to the emergence of drug resistance. Click chemistry, particularly, the 
copper(I)-catalyzed reaction between azides and alkynes has shown to have a cutting-
edge advantage in medicinal chemistry by its reliability, selectivity and biocompatibility. 
Triazole-based antimalarials were synthesized via copper(I)-catalyzed alkyne-azide 
cycloaddition reaction by modifying the aliphatic chain terminal of chloroquine. The 
compounds synthesized contain triazole ring directly connected to an aromatic ring or via 
a piperazine linker. When tested for their in vitro antimalarial activity against D6, Dd2 
and 7G8 strains of P. falciparum, 12 out of 28 compounds showed better activity against 
chloroquine resistant strains. Particularly, PL403 and PL448 exhibited potent activity 
than chloroquine against CQ-resistant strains Dd2 and 7G8, with IC50 values of 12.8 & 
14.5 nM, and 15.2 & 11 nM respectively.  
The efficiency of synthesizing several triazole-based antimalarials have proven click 
chemistry to be fast and efficient reaction. Generally, para-substitutions and di-
substitutions with electron-withdrawing groups were found to be beneficial for having 
better antimalarial activity for these group of click compounds. Moreover, the 
incorporation of piperazine linker has brought an enhanced antimalarial activity. 
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CHAPTER 1: Malaria 
1.1. Introduction and Epidemiology 
Malaria is a tropical infectious disease considered as one of the most prevalent and 
debilitating diseases affecting humans.
1
 There are 3.4 billion people at risk of malaria 
transmission in 106 countries and territories. The WHO estimates 198 million cases of 
malaria and an estimated 584,000 deaths, many of them are children living in sub-
Saharan Africa where a child dies every minute.
2
 Malaria was eliminated from the United 
States in the early 1950's. However, 1500 – 2000 malaria cases are reported every year in 
the US from recent travelers.
3 
 
 
Figure 1.1. % population at risk in 2013
2 
 2 
 
 
1.2. Cause and Transmission 
Malaria is caused by infection with protozoan parasites belonging to the genus 
Plasmodium transmitted by female Anopheles mosquitoes.
4
 Although over 200 species of 
Plasmodium genus are existing, only five affect humans: P. falciparum, P. vivax, P. 
ovale, P. malarie and P. knowlesi.
5
  
  
Figure 1.2. Life cycle of Plasmodia species
11 
Plasmodium falciparum is the most virulent form which causes potentially fatal cerebral 
malaria. It’s characterized by high levels of parasitaemia and is responsible for about 
 3 
 
80% of human malaria worldwide.
1, 5
 Relapse is common with P. vivax and ovale due to 
the dormant stage (hypnozoites) persisting in the liver and invading the blood stream in 
later years. While P. vivax and P. ovale selectively infect young cells, P. malariae 
parasitizes older cells.
6
 P. knowlesi is considered as a parasite of monkeys that can cause 
fatal infections in humans.
7
 
Species Clinical features Endemic areas 
Plasmodium 
falciparum 
Tertian non-relapsing malignant 
malaria 
Sub-Saharan Africa, Latin 
America, South-East Asia 
Plasmodium 
vivax 
Tertian relapsing benign 
malaria 
South-East Asia, Latin 
America, Sub-Saharan Africa 
Plasmodium 
ovale 
Tertian relapsing benign 
malaria 
South-East Asia, Pacific, East 
Africa 
Plasmodium 
malariae 
Quartan non-relapsing benign 
malaria 
West Africa, Guyana, India 
Plasmodium 
knowlesi 
Quotidian, Severe malaria may 
occur 
South-East Asia 
Table 1.1. Clinical features and geographical distribution of Plasmodia species
8
 
The malaria parasite life cycle involves two hosts: human and mosquito.  During a blood 
meal, a Plasmodium-infected female Anopheles mosquito inoculates sporozoites into the 
human host.  Sporozoites infect liver cells and mature into schizonts, which rupture and 
release merozoites. At this stage they can also remain dormant as hypnozoites.
9
 After the 
initial replication in the liver, the parasites undergo asexual multiplication in the 
erythrocytes. Merozoites infect red blood cells. The ring stage trophozoites mature into 
schizonts, which rupture releasing merozoites. Some parasites differentiate into sexual 
erythrocytic stages (gametocytes). Blood stage parasites are responsible for the clinical 
manifestations of the disease.
10
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The gametocytes, male and female, are ingested by an Anopheles mosquito during a 
blood meal. While in the mosquito's stomach, the microgametes penetrate the 
macrogametes generating zygotes. The zygotes in turn become motile and elongated 
ookinetes which invade mosquito gut where they develop into oocysts.
11 
The oocytes give 
birth to sporozoites in the gut of a female mosquito. These migrate to the mosquito's 
salivary glands, and are injected into humans. Inoculation of the sporozoites into a new 
human host perpetuates the malaria life cycle.
12
  
1.3. Symptoms and Diagnosis 
Following an infective bite by female Anopheles mosquito, the infected person starts to 
show symptoms after 1 to 4 weeks. The most common symptoms of malaria include 
fever, chills, sweating, headaches, fatigue, nausea, and vomiting.
13
 In P. falciparum 
malaria, untreated patients present more pernicious manifestations such as cerebral 
malaria, hypoglycemia, acute renal failure, metabolic acidosis, severe anemia, and 
pulmonary edema.
14
 Severe anemia is a major cause of morbidity and mortality among 
children in the developing countries. 
Microscopy is the basis for diagnosis of malaria providing information about the species 
and the density of Plasmodium. Polymerase chain reaction (PCR) is also used when the 
detection limits of parasites is below microscopy.
15 
Antigen-detecting RDT detects 
Plasmodium antigen by an antibody–antigen reaction on a nitrocellulose strip.16 Antibody 
could also be detected by ELISA after exposure to the parasites. Moreover, hemozoin, a 
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by-product of Plasmodium metabolism, has been used to detect both the disease and the 
species via the absorbance of laser light  at specific frequencies.
17 
1.4. Treatment and Prevention 
The Malaria Eradication Research Agenda (malERA) addressed several issues in malaria 
elimination campaigns. It focuses on integrated research agenda which is essential in 
making pragmatic decision for shifting from control to elimination.
18
 The global malaria 
control strategy aims to halt the exacerbating situation of malaria by minimizing waste of 
resources and improving health services.
19
  
Insect repellents could provide useful protection against malaria, especially in places 
where vector mosquitos bite early in the evening.
20 
Indoor residual spraying (IRS), 
mainly through the use of the insecticide DDT (dichloro-diphenyl-trichloroethane) has 
been an important component of malaria control. Despite attempts to ban DDT 
completely because of issues such as effect on preterm births and lactation duration, the 
compound continues to be used in parts of Asia and Africa.
20, 21
 
Vector control is also an essential component of prevention.
21
 Insecticide-treated nets 
(ITNs) have consistently shown reductions in overall child mortality and in episodes of 
clinical malaria.
20
 In areas of moderate or high transmission in Africa, deployment of 
pyrethroid insecticide-treated mosquito nets reduced all-cause mortality by roughly 20% 
in children younger than 5 years.
21 
ITNs are more beneficiary than IRS as they both 
protect the individual user against biting and kill some of the mosquitoes that try to bite. 
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Deltamethrin and Permethrin are the most commonly used  insecticides constituting 
about 60 and 22% of the global usage respectively.
22 
The genome of Anopheles gambiae, one of the most efficient vectors of malaria,  has now 
been sequenced providing candidate genes in generating Genetically Modified 
Mosquitoes (GMM).
24
 This 20-year old program uses site-specific gene recombination 
technologies to insert the antipathogen effector genes in the integration sites of the 
genome to develop A. gambie that are fully refractory to plasmodium.
22
  
Drug chemoprophylaxis has also proved to be one of the most effective preventive 
strategy especially for travellers to malaria endemic areas. It is essential to emphasize that 
no chemoprophylactic regimen gives complete protection and must always be 
accompanied by primary protection such as ITN and insect repellants. The prophylaxis 
drug should be continued to be taken for at least 4 weeks after the last possible exposure 
to take into account for the pre-erythrocytic phase of the plasmodial cycle.
8 
Common antimalarials used as chemoprophylactic agents include chloroquine, proguanil, 
mefloquine, doxycycline, primaquine and tefenoquine. Proguanil in combination with 
chloroquine and atovaquone (Malorone) is also administered. Some antimalarial drugs 
that have well established therapeutic roles have no rational use as malaria 
chemotherapeutic agents (Table 2). Although chloroquine is less useful as 
chemoprophylaxis in most places, it is still used in Central America and Hispaniola. In 
the US, mefloquine (1989), doxycycline (1992) and atovaquone/proguanil (2001) are the 
three currently approved drugs for malaria prevention.
8, 25 
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Antimalarial drug Severe adverse event or contraindication 
observed 
Amodiaquine agranulocytosis and hepatotoxicity 
Halofantrine cardiac dysrhythmias 
Pyrimethamine-dapsone Agranulocytosis 
Pyrimethamine-
sulfadoxine 
severe skin reactions (e.g. Stevens-Johnson 
syndrome) 
Quinine long-term use predisposes to blackwater fever 
qinghaosu derivatives 
(i.e. artesunate) 
severe CNS lesions in animal studies in long-term 
use of these short-acting drugs 
Table 1.2. Medications that should not be used for malaria chemoprophylaxis 
 
The WHO recommends occupational and long-term travellers to carry Stand-By 
Emergency Treatment (SBET) drugs for self treatment when medical care is not 
accessible within 24 hours from onset of exposure and symptoms. Combination drugs 
used for uncomplicated P. falciparum malaria such as artemether/lumefantrine, 
atovaquone-proguanil, quinine plus doxycycline or clindamycin can be used as SBET 
drugs.
8
 
Almost two decades have been spent on development of malaria vaccines. So far, most 
efforts have been put in developing pre-erythrocytic stage vaccines designed to destroy 
infected hepatocytes or prevent their invasion by sporozoites.
20
 RTS,S/AS01 is a hybrid 
molecule in which the circumsporozoite protein of P. falciparum is expressed with 
hepatitis-B surface antigen (HBsAg) in yeast and boosted with the potent ASO 
adjuvant.
21
  
In coincidence with World Malaria Day 2015, the RTS,S Clinical Trials Partnership 
reported final results of a Phase 3 trial of the RTS,S/AS01 vaccine which were conducted 
in seven countries in Africa. After 38 and 48 months, the results indicated 25.9 and 
 8 
 
36.3% protection in children at 6-12 weeks and 5-7 months respectively when 3 doses 
were given at 0, 1, 2 with a booster at 20 months or a control vaccine.
26
  
Moreover, various medicinal plants are reported to possess insect-repellent activity 
against mosquitoes including Azadirachta indica, Lantana camara, Vitex negundo, 
Mentha piperita, Tagetes minuta, Eucalyptus and Cymbopogon species.
23
 In some 
definite epidemiological situations, environmental management activies comprising 
drainage of mosquitoes breeding sites, house design improvements and utilising 
larvivorous fish have proved to be effective.
20
 
1.5. Antimalarial Chemotherapy 
When malaria prevention fails and a person is infected by the parasite, several treatment 
options are available. The treatment depends on the type the Plasmodium species, the 
stage of the parasite, the mechanism of action and the half life of the drug. 
Quinine was the first natural antimalarial extracted from the bark of cinchona tree in Peru 
around the 17
th
 century. It was the pioneer drug and has been used for more than two 
centuries until its resistance emerged.
27
 In addition, the common side effect symptoms of 
cinchonism associated with it decreased its use. Because of resistance, quinine is taken in 
combination with secondary agents such as doxycycline, clindamycin or SP. Although its 
sterioisomer, quinidine, could be given IV for P. falciparum malaria, it is basically 
indicated as anti-arrhythmic.
29
 
The 4-aminoquinolines are an important class of antimalarials which comprises of 
chloroquine, amodiaquine and piperaquine.
27
 Chloroquine is one of the classic drugs 
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which became a mainstay for malaria treatment in the mid-20
th
 century. Chloroquine and 
amodiaquine have blood schizontocidal effects against asexual stages of the parasite in 
blood.
28
 Despite the reported cases of hepatotoxicity and agranulocytosis for 
amodiaquine, the lack of new drugs for drug-resistant malaria made it attractive.
29
  
Another important class are the 4-methanoquinolines including mefloquine, halofantrine 
and lumifantrine.
27 
In addition to neuropsychiatric side effects, drug resistance in 
southeast asia has limited the use of mefloquine. Halofantrine is another aminoalcohol 
effective for treating chloroquine-resistant malaria, but cardiotoxicity is associated with 
its use. Lumefantrine is a racemic fluorene derivative which is only available in 
coformulation with artemether.
29
 
Primaquine, pamaquine and bulaquine belong to a class of 8-aminoquinolines.
27
 
Primaquine is one of the few drugs effective against both gametocytes of P. falciparum 
and hypnozites of P. vivax and P. ovale. However, its short half-life (6 hrs) makes it 
contraindicated in patients with G6PD deficiency, because it has to be taken for two 
weeks to overcome relapse in P. ovale and vivax infections.
28
  
Artemisinin belongs to a class of sesquiterterpene lactones, extracted from a sweet 
woodworm Artemisia annua.
29 
Artemisinin derivatives such as artemether, artesunate and 
arteether have been used recently in China and SE Asia for the management of malaria. 
Their high gametocidal effect and low resistance profile made them the mainstay 
combination therapy.
28
 Unfortunately artemisinin can not be used alone due to its short 
half-life, and hence the WHO highly recommends administration of ACTs. It has been 
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suggested that these endoperoxides act by damaging Sarco-Endoplasmic Reticulum Ca
2+
-
ATPase (SERCA).
29 
 
Figure 1.3. Currently available antimalarial drugs 
Atovaquone is a hydroxy-naphthoquinone which acts by collapsing mitochondrial 
membrane potential of the parasite.
27
 It’s usually used for treatment and prevention of 
chloroquine-resistant P. falciparum in combination with proguanil (Malarone). Proguanil 
is a biguanide antifolate that synergistically acts by reducing the concentration of 
atovaquone needed.
29
 
Sulfadoxime and pyrimethamine are antifolate inhibitors which inhibit DNA synthesis of 
the parasite by specifically targeting dihydropteroate synthase and dihydrofolate 
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reductase enzymes. SP (Fansidar) is very effective when administered in combination 
with amodiaquine.
29
 Dapsone is another sulfone drug used with chlorproguanil (lapdap), 
although withdrawn due to its hemolytic toxicity. Antibiotics are also recommended for 
use in quinoline-resistant strains. Tetracyclines (tetracycline & doxycycline) and 
macrolides (clindamycin & azithromycin) act by inhibiting RNA synthesis. They are very 
beneficial in  combination therapy with quinine.
31 
Research and development of new and recycled antimalarial drugs is still in progress, and 
many drugs are in their preclinical and clinical phases. 4-aminoquinoline drugs such as 
AQ-13 and N-tert-butyl-isoquine (GSK369796) are analogues of chloroquine and 
amodiaquine which are in Phase II clinical and Preclinical trials respectively. AQ-13 is 
being studied for uncomplicated P. falciparum malaria but there is a concern of cross 
resistance with chloroquine.
33
 N-tert-butyl-isoquine is highly effective and possesses 
better overall preclinical safety profile than chloroquine or amodiaquine.
34
 
Tefenoquine and NPC-1161B are 8-aminoquinolines under inverstigation for the 
treatment of the hypnozoite stages of P. vivax and P. ovale that are responsible for 
relapse of these malaria species. Tefenoquine has an advantage over primaquine in that it 
is long acting (2-3 weeks) for treating liver stages of P. vivax. Tafenoquine is currently in 
late stage development as an anti-malarial prophylactic agent, and NPC-1161B is in late 
preclinical development.
35
  
The disadvantages of semisynthetic artemisinin derivatives are their short half-lives, 
dependence on plant source for starting material, and alarming reports of ACT treatment 
failures which call for a need for new analogues to this class of antimalarials.  OZ277 
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(Arterolane) was the first synthetic ozonide to be evaluated clinically and is now 
launched in India in combination with piperaquine, and has obtained regulatory approval 
to introduce in seven African countries. 
OZ439 is another improved synthetic ozonide candidate designed to provide a single-
dose oral cure in humans. It has successfully completed Phase I clinical trials and is 
currently undergoing Phase IIb trials in malaria patients in combination with piperaquine. 
When compared to OZ277 and other former endoperoxides, OZ439 is active against all 
asexual erythrocytic stages of P. falciparum and exhibits a substantial increase in the 
pharmacokinetic half-life.
36 
 
Mutations on dihydrofolate reductase enzyme compromised the efficacy of antifolate 
drugs. Research in developing new antifolates such as P65, P218, and WR99210 is in-
advance. P218 has proven to potently inhibit both wild-type and clinically relevant 
mutated forms of Plasmodium falciparum. Its suitable pharmacologic and safety profile 
made it to be an oral antimalarial candidate among this class.
37
 KAE609 (Cipargamin) is 
a first-in-class agent with a new mechanism of action by inhibiting pfATP4 (Ca
2+
-
ATPase). This spiroindolone showed a rapid antimalarial activity in phase II clinical trial 
for the treatment of uncomplicated P. falciparum and vivax malaria.
38 
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Figure 1.4. Antimalarial drug candidates in clinical development 
1.6. Resistance to Antimalarial Drugs 
The plasmodium parasite developed acquired resistance to antimalarial drugs. The type of 
the resistance varies with the species, the strain, and the drug used. Many factors account 
for the development and spread of resistance including drug-use patterns, characteristics 
of the drug, host factors, parasite characteristics, vector, and environmental factors.
39
  
Drug resistance to several novel antimalarial drugs has been reported when used as 
monotherapy and combination drugs. Plasmodium falciparum is the main concern and 
cause of resistance among the five species. Chloroquine resistance to P. vivax is largely 
concentrated in Indonesia and Papua New Guinea. Chloroquine retained adequate 
efficacy against P. ovale and P. malariae, but delayed parasite clearance times is 
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observed.
40
 There are recent reports of treatment failure and clinical resistance to 
artemisinin-based therapy in western Cambodia.
41
 
 
Figure 1.5. Approximate dates of introduction and treatment failure of antimalarial drugs 
[Abbreviations: Chloroquine (CQ), Atovaquine-Proguanil (PG), Pyrimethamine (Pyr), Quinine (Q), 
Sulfadoxine (SDX), Artimisinin and derivatives (Art), Mefloquine (Mef), Halofantrine (Hal), Atovaquone 
(Ato) , LapDap: Chlorproguanil–Dapsone (LD), Resistance (R), Combinations (Comb)]. 42
 
Genetic mutations in P. falciparum strains have been linked with phenotypes of clinical 
resistance and putative markers have emerged and reported.
39 
Gene Product Genetic Determinant Drug 
pfcrt Transporter Thr76 Chloroquine 
pfmdr 1 Transporter Tyr86 Chloroquine, mefloquine, quinine, 
dihydroartemisinin, artesunate  
 
dhps Dihydropteroate 
 Synthetase 
Gly437, Glu540,  
Gly581 
Sulfadoxine 
dhfr Dihydrofolate  
 Reductase 
Asn108, Arg59,  
Ile51, Leu164 
Pyrimethamine 
cytb Cytochrome b Ser268 Atovaquone 
Table 1.3. Mutations in P. falciparum associated with resistance to antimalarial drugs
39
 
In order to counter drug resistance and delay the emergence of more resistance, many 
combination therapies have been adapted. The drugs to be used in combined therapies 
might require to have separate mechanisms of action against same stage of the parasite. 
Artemisinin derivatives along with other antimalarial classes present effort towards 
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achieving such therapeutic level.
39 
Current combination regimens recommended by the 
WHO include artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, 
and artesunate-SP.
31
 
1.7.Reversed Chloroquines  
Chloroquine (Resochin) was first synthesized in 1934 by a German chemist, Hans 
Andersag, by modifying mepacrine, replacing the acridine ring with a quinoline ring.
43
 
Chloroquine is a weak base containing a side-chain diethylamine nitrogen (pKa = 10.2) 
and a quinoline ring nitrogen (pKa = 8.1). It is administered as a racemic mixture of two 
enantiomers of which the (+)-CQ enantiomer is more potent against CQ-resistant strains 
of P. falciparum than the (-)-chloroquine enantiomer.
45
 Chloroquine is indicated for 
treatment and prevention of acute uncomplicated malaria.
47
 
Chloroquine could be administered in oral, subcutaneous, intramuscular and rectal routes. 
When taken orally, CQ is rapidly absorbed from GI tract with bioavailability of 75-
80 %.
45
 It has an onset of action of 1-2 hrs and half-life of  3-6 days.
45
 CQ is metabolized 
in liver by CYP3A, CYP2C8, and CYP2D6 enzymes to mono-desethyl CQ (30-40%) and 
bisdesethyl CQ (5-10%).
45 
The CQ side chain is further dealkylated to form 7-chloro-4-
aminoquinoline. About 70% of the ingested drug is excreted unchanged in  urine.
45
 
CQ targets the biochemical pathway in the acidic digestive vacoule (DV) of P. 
falciparum. Heme released during metabolism of hemoglobin biocrystallizes to inert 
hemozoin by the Plasmodium parasite. CQ accumulates in the DV and blocks heme 
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biocrystallization to hemozoin by forming cytotoxic CQ–heme complexes and other 
mechanisms that kill the parasites by making the cell-membrane permeable.
46
  
 
Figure 1.6. Mechanism of action of CQ and electron micrograph of the DV
48
 
In the DV of Plasmodium falciparum (pH = 5.5), CQ is trapped at high concentration in 
its doubly protonated and membrane-impermeable form.
47
 The CQ-resistant strain 
accumulates 4-10 times less CQ than CQ-sensitive strains of P. falciparum, thus the 
intracellular CQ concentration will be less toxic to the parasite.
46
 
Chloroquine is effective, cheap, and safe to children and pregnant women. It has been 
one of the most successful antimalarials ever developed and used as the most reliable 
firstline prophylaxis for 40 years. The first cases of resistance were reported from South 
America in 1961. The resistance to CQ is linked to mutation in the DV membrane protein 
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of Plasmodium falciparum chloroquine resistant transporter (PfCRT).
44
 The change from 
lysine (K) to threonine (T) in the transmembrane domain of PfCRT appears to be 
required for the resistance.
49
  
Parasite type and origin PfCRT position and encoded aminoacid 
72 74 75 76 97 220 271 326 356 371 
Chloroquine sensitive 
   Wild type C M N K H A Q N I R 
   106/1 (reverant) C I E K H S E S I I 
Chloroquine resistant 
   Southeast Asia & Africa, type E1a C I E T H S E S T I 
   Southeast Asia & Africa, type E1b C I E T H S E S I I 
   Papua New Guinea, type P1 S M N T H S Q D L R 
   South America, type W1a S M N T H S Q D L R 
   South America, type W1b C M N T H S Q D L R 
   South America, type W2 C M E T Q S Q N I T 
Table 1.4. Mutant forms of PfCRT and association of the K76T marker with chloroquine    
resistant P. falciparum from different geographic regions
50
 
 
Several reversal agents or chemosentisezers that reverse the resistance by inhibiting the  
efflux of chloroquine via membrane transporters of the DV of Plasmodium falciparum 
resistant strain have been reported. Verapamil and two other calcium channel blockers, 
vinblastine and daunomycin, are among the first drugs reported that slowed the release 
and increased the accumulation of chloroquine by resistant P. falciparum.
52
  
Subsequently the reversal effect of tricyclic antidepressant, desipramine, and selective 
serotonin re-uptake inhibitor (SSRI), fluoxetine, were reported.
53, 54
 Fluoxetine showed an 
increased reversal activity than verapamil when tested against CQ-resistant W2 clone of 
P. falciparum.
54  
Antihistamines such as chlorpheniramine (racemic) and promethazine also showed 
reversal of chloroquine resistance in vitro against CQ-resistant P. falciparum.
55,56 
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Combination of chemosentisizers had also displayed an additive effect in potentiating CQ 
accumulation in the DV of the resistant parasite.
57
 The antimalarial drug, primaquine, 
also has a synergic activity with chloroquine and it blocks PfCRT.
58 
It was implicated by 
recent study that the mutant PfCRT uses reversal agents such as verapamil, 
chlorpheniramine, desipramine, prometazine, fluoxetine and primaquine as substrates.
59 
 
Figure 1.7. Pharmacophore of chloroquine reversal resistance
60
 
Bhattacharjee et al. have developed a pharmacophore for reversal agents.
60
 The 
pharmacophore has a general structure of two aromatic hydrophobic groups and a 
hydrogen bond acceptor, preferably at a side chain nitrogen atom. The class of drugs 
which qualify for this pharmacophore include calcium channel blockers, antihistamines, 
tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRI’s). 
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Figure 1.8. Structures of known CQ-resistance reversal agents used as pharmacophores
 
 
To circumvent chloroquine resistance, reversed chloroquines were designed in Peyton 
lab. These are hybrid drugs comprising quinoline nucleus and reversal agent moiety. In 
earlier studies, the tricyclic antidrepressant drug, imipramine, showed the highest potency 
when tested for its CQ resistance reversal effect against W2 clone of P. falciparum. 
61 
The first hybrid molecule, PL01, was synthesized by linking chloroquine moiety  and  
imipramine as a RA. The hybrid analogue was found to be very effective against both 
CQ-sensitive and CQ-resistant strains of P. falciparum when compared to chloroquine.
62 
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Modifications were made to PL01 to increase the oral availability. As a result a lead 
antimalarial drug candidate, PL69, was developed. It was found to be effective for CQ-
resistant malaria in vitro.  The IC50 values of PL69 against D6, Dd2, and 7G8 strains of 
P. falciparum were 0.9, 1.6, and 1.8 nM, when compared to CQ values of 6.9, 102, and 
106 nM. PL69 was also orally available in a mouse model of malaria. In vivo, it cured 
mice infected with P. berghei at <64 mg/kg/day, which is equimolar dose with of 
chloroquine.
63
 
            
 
Figure 1.9. The hit (PL01) and the lead (PL69) RCQ’s synthesized in Peyton lab 
Moreover, the mechanism of action was indicated to be similar to CQ, by inhibiting the 
formation of hemozoin. PL69 (DM1157) is now in late-stage preclinical studies by 
DesignMedix. This lead RCQ candidate has physico-chemical features that makes it a 
favourable partner drug for antimalarial combination therapy. The drug discovery 
research is still on progress to furnish more back-up drugs for the pipeline.
64  
 
 
 
PL01 PL69 
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CHAPTER 2: Click Chemistry
 
2.1. Introduction 
Nature’s giant molecules are constructed from a small building blocks by few types of 
reactions for connecting them together. Biological macromolecules such as 
polysaccharides, proteins and nucleic acids are all condensation polymers of small 
subunits formed by carbon-heteroatom bonds. Following Mother Nature’s strategy, 
Sharpless, Kolb, and Finn identified a group of reactions and developed an approach 
called ‘Click Chemistry’ in 2001.65 The main objective of click chemistry was to develop 
an array of selective, powerful and modular blocks which are reliable and have wide 
application.
66 
Sharpless and coworkers have set criteria that a process must meet to fulfill these 
reactions: “The reaction must be modular, wide in scope, give very high yields, generate 
only inoffensive by-products that can be removed by non-cromatographic methods, and 
be stereospecific (but not necessarily enantioselective). The required process 
characteristics include simple reaction conditions, readily available starting materials 
and reagents, the use of no solvents or a solvent that is benign (such as water) or easily 
removed, and simple product isolation.’’ 66,67 
Finn and Fokin have developed common attributes of click reactions that many click 
compounds are derived from alkenes and alkynes, and that the bond is formed between 
carbon and heteroatom (mostly N, O & S). In addtion click reactions are strongly 
exothermic and are usually either fusion or condensation processes. Moreover, many 
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click reactions are highly tolerant of water. In point of fact, they are often accelerated by 
the presence of water.
68 
2.2. Types of click reactions 
There are mainly four types of click reactions that use olefins and acetylenes as their 
carbon framework for forming carbon-heteroatom bond. These reactions include:
 
- Cycloaddition reactions: for example hetero-Diels-Alder and 1,3-dipolar 
cycloadditions 
- Nucleophilic ring-opening on strained heterocyclic electrophiles including 
epoxides, aziridines, cyclic sulfates & sulfamidates and aziridinium & 
episulfonium ions
69
 
- Non-aldol carbonyl chemistry including formation of oxime ethers, hydrazones 
and aromatic heterocycles 
- Addition to carbon–carbon multiple bonds such as epoxidation, dihydroxylation, 
aziridination, and nitrosyl and sulfenyl halide additions
70
 
2.3. Huigsen 1,3-Cycloaddition reactions 
The potential and the mechanism of 1,3-dipolar cycloaddition reaction between alkynes 
and azides to form 1,2,3-triazoles was unveilled by Huisgen et al. in the 1960s.
71 
However, the reaction was not utilized to its full extent until the copper(I)-catalyzed 
Azide-Alkyne cycloaddition (CuAAC) version reaction is discovered.
72 
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Scheme 2.1. Click Chemistry – energetically highly favorable linking reactions 
The potential of this reaction is very high due to the wide range of substituents involving 
alkynes and azides. Several triazoles have been made by using the Huigsen 1,3-
cycloaddition reaction before the advent of catalysed reactions. Pearson et al. described 
the synthesis of monosubstituted dihydropyrrolo-1,2,3-triazole analogue of antitumor 
dehydropyrrolizidine alkaloid using an intramolecular azide–alkyne cycloaddition, by 
refluxing the azide in toluene in 55% yield.
73 
Nevertheless, this reaction has suffered a lack of selectivity for more than 40 years 
because of the weak directing effect of the substituents yielding a mixture of the 1,4- and 
the 1,5-regioisomers. Another disadvantage of this reaction is that the formation of 
products require long heating and the two regioisomers are challenging to separate using 
classical chromatographic procedures.
74 
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Scheme 2.2. Synthesis of antitumor dehydropyrrolizidine analogue 
When the reactants are heated without a catalyst, mixture of 1,4 and 1,5-triazoles are 
formed. When the reaction is catalysed by ruthenium, only the 1,5-regioisomer is formed. 
This was shown by Imperio et al. on the synthesis of Steganacin and Podophyllotoxun 
analogues to replace the lactone ring by 1,5-disubstituted triazole selectively.
75 
However, 
the copper catalysed azide-alkyne cycloaddition (CuAAC) reaction produces only the 
1,4-regioisomer.
 
 
Scheme 2.3. The 1,3-dipolar cycloaddition between azides and alkynes 
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2.4. Copper catalysed Azide-Alkyne cycloaddition 
The copper(I)-catalyzed cycloaddition reaction between azides and terminal alkynes to 
give 1,4-disubstituted 1,2,3-triazoles has become the benchmark of ‘click chemistry’. 
This reaction is very reliable, selective, biocompatible and exhibits a broad scope.
76 
It 
was reported that the copper (I) salts were able to accelerate the reaction by up to 10 
million times.
 77,80 
One of the starting materials, azide, has a unique advantage of  stability towards H2O, O2 
and other organic synthetic conditions. Azide and alkyne functional groups are not 
reactive to other functionalities because of their high kinetic barrier.
81 
Usually the 
reaction proceeds to completion in 6-36 hours at ambient temperature (room temperature 
to 50
0
C). The catalyst is prepared in situ by reducing Cu(II) to Cu(I) salts using sodium 
ascorbate/ascorbic acid to get a cheaper and purer source. Sodium Ascorbate has proven 
to be an excellent reducing agent at 0.25-2% catalyst concentration.  
The common solvents used include mixture of tert-butanol/ethanol and water without 
using any additional organic solvent. However, when reducing agent is not used, 
copper(I) salts including CuI and CuOTf : C6H6 can be used directly by utilizing one 
equivalent of nitrogen base (triethyl amine, DIPEA) in a cosolvent (acetonitrile, 
tetrahydrofuran, dichloromethane and toluene).
77 
The CuAAC is a very versatile reaction in that it proceeds best in aqueous systems 
including serum and whole blood, over a broad temperature range (0-160°C). Its 
remarkably insensitivity to wide range of pH (4 to 12) and stable to redox degredation 
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made the reaction to succeed beyond limit in the presence of all functional groups tested 
to date. 
78 
 
Figure 2.1. Proposed catalytic cycle for the CuAAC reaction 
The proposed catalytic mechanism suggests that the 1,3-dipolar cycloaddition of terminal 
alkynes and azides is catalyzed by copper(I) salts via the formation of copper−acetylide 
complex, followed by a stepwise or concerted addition to an azide. This mechanism 
makes the catalysis not to be functional on internal alkynes.
80
 
2.5. Applications of Click Chemistry 
Click chemistry is originally developed for assisting medicinal chemists to have a 
triumph over combinational chemistry issues. Based on solution-phase library synthesis, 
Lexicon Pharmaceuticals synthesised 200,000 compounds of acceptable purity on 25-50 
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mg scale using click chemistry. The application of click chemistry is wide ranging from 
drug discovery to material science.
81 
The applicability of click chemistry in bioconjugation involves the attachment of 
synthetic labels to biomolecular framework covalently. CC enables lengthy 
bioconjugation processes of 60 steps with more than 99.8% yield. The bioorthagonal 
properties and solvent tolerance make azides and alkynes very important groups in 
bioconjugation.
82
 The first application of CC in bioconjugation was shown by making 
1,4-substituted [1,2,3]-triazoles in peptide backbones.
80
 Because the presence of copper 
in CuAAC may create hinderance to bioorthogonal conjugation in living systems, copper-
free click chemistry is applicable using Dibenzcyclooctyl (DBCO) as a source of alkyne. 
After introduction of CC, its significance in materials science, specifically in polymer 
synthesis, was demonstrated by the synthesis of triazole-based dendrimers. The unique 
properties and application made dendrimers to receive much attention. The main problem 
in the purification during dendrimer synthesis was solved by the fidelity of CuAAC.
83
 
The first triazole-based dendrimer was synthesiszed by sequential click reactions on bis-
alkynyl scaffold flexible with an azide anion substitution. The ability of polydentate 1,4-
disubstituted 1,2,3-triazole ligands to stabilize Cu(I) species under physiologic conditions 
has proven vital applicaton in biological systems.
84 
Click chemistry has shown to have a cutting-edge application in the demanding world of 
medicinal chemistry in developing novel approaches to screening compound libraries. 
One of the main reason which makes CC reliable in drug discovery is that the compounds 
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can be screened directly from the reaction mixture. This was shown in the discovery of 
Human r-1,3-fucosyltransferase enzyme when the Cu(I)-catalyzed triazole synthesis  was 
utilized to create library of GDP (guanosine diphosphate)-triazole candidates as the crude 
aqueous reaction were tested directly.
85 
The other applications of click chemistry include 
glycoscience, peptide chemistry, supramolecular chemistry, oligonucleotide synthesis and 
others.
82 
2.6. Click chemistry in Drug discovery 
It is a challenging task for medicinal chemists to develop new patentable drugs with 
strong activity and good ADMET properties in short time. The triazole-forming Click 
chemistry accelerates drug discovery in hit finding and lead optimization due to its 
reliance on extremely quick reactions in high yield.
 
Most of triazole containing drugs available so far are enzyme inhibitors, receptor ligands, 
peptides, and modified natural products. There are few drugs available on the market or 
in clinical trials  including anticancer carboxyamidotriazole (CAI), the nucleoside 
derivative non-nucloside reverse transcriptase inhibitor Tert-
butyldimethylsilylspiroaminooxathioledioxide (TSAO), β-lactum antibiotic Tazobactum 
and the cephalosporine cefatrizine.
76
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Figure 2.2. Drugs based on 1,2,3-triazoles
76 
Before Click chemistry came into action, several molecules that contain 1,2,3-
triazole moiety were synthesized using various methods. These include 
anticancer, antibacterial, antimalarial, antifungal, antitubercular, antiviral, 
antihypertensive, and hypocholesterolemic agents.
76 
Pisaneschi et al. synthesized 3-cyanoquinoline-based fluorinated compounds that would 
make a good imaging agent for epidermal growth factor receptor (EGFR) to  facilitate the 
clinical evaluation of  tumors. One of the 20-fluoroethyl-1,2,3-triazoles showed to have 
good cellular potency, low lipophilicity and good metabolic stability in vitro to be a 
promising radiotracer for imaging of EGFR status.
86
 Another new class C5- curcuminoid-
4-aminoquinoline molecular hybrids has shown potential anticancer activity when tested 
on 60 human cancer cell lines at nM concentration.
87 
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                           Pisaneschi et al.                                     Rawat et al. 
Figure 2.3. Triazole based anticancer molecules 
The application of Click chemistry of 1,2,3-triazoles in synthesizing new class of 
antifungal and antimicrobial agents is becoming prevalent.
76
 A series of substituted 
triazoles were synthesized using 1,2,3-triazole containing quinoline moiety and tested for 
their antimicrobial and antifungal activity. SAR investigation revealed that the nature of 
the substituent on the 4-position of the triazole ring influences the antimicrobial activity. 
When evaluated for in vitro activity and compared with standard antifungal Cyclo-
piroxolamine, the 3-methylthien-2-yl moiety showed a broad spectrum antimicrobial 
activity against all tested strains.
88 
Two substituted 1,2,3-triazoles containing quinoline moiety showed good antibacterial 
and moderate antifungal activity, particularly the compounds with 3-methyl thienyl 
substituents are found to have increased antimicrobial activity.
89 
In other study, Thomas 
and co-workers reported in vitro activity of similar antibacterials and antifungals. The 
compounds demonstrated moderate to very good activities, when comparable to 
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Ciprofloxacin and Ciclopiroxolamine respectively. The enhanced activity is due to the 
presence of active piperazine and its derivatives in their structures.
90 
                         
             Sumangala et al                   Holla et al                                  Thomas et al 
Figure 2.4. Triazole based antibacterial and antifungal molecules 
Olomola et al synthesized anti-HIV triazole-based hybrids using Cu(I)-catalysed 
cycloaddition reaction by combining 3-alkynylmethylcoumarins with azidothymidine 
(AZT). The structurally complex coumarin-AZT conjugates have the potential dual-
action as HIV-1 protease and non-nucleoside reverse transcriptase inhibitors.
91 
 
Figure 2.5. Triazole based anti-HIV hybrid molecule 
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2.7. Triazole based Antimalarials 
The modification of well-established antimalarials, particularly chloroquine is very 
common in making new drugs to counteract drug resistance. Different groups reported 
the synthesis of 1,2,3-triazole based quinoline moieties using copper(I)-catalysed 
cycloaddition click chemistry. 
A series of 4-aminoquinoline-1,2-3-triazole based hybrids were synthesized and 
evaluated for their in vitro antimalarial acivity against D6 and W2 strains of P. 
falciparum. Some of the compounds have shown promising antimalarial activity without 
showing any toxicity against Vero cells.
92 
On the similar studies done by Mamgain et al., 
the absence of linear alkyl chain linker have shown to diminish the antimalarial activity.
93 
Pereira et al directly clicked 7-chloroquinoline with different substituents in position C4 
of the quinoline at the N1 of the triazole ring. When evaluated for their in vitro activity 
against P. falciparum (W2), the compounds showed moderate antimalarial activity and 
low cytotoxicity to Hep G2A16 cells. The decreased activity was explained by the low 
resonance contribution of the triazole ring to stabilize the acidic form of the quinoline 
ring that decreases the pKa of the quinoline nitrogen.
94 
Another set of triazole molecules was made by the Blackie group using the mefloquine 
pharamacophore by CuAAC chemistry. The in vitro biological activity of the compounds 
on NF54 chloroquine-sensitive strain of Plasmodium falciparum was determined to be in 
the lower l.0 uM range. The authors concluded that the inclusion of the piperazine does 
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not appear to be advantageous in biological activity because the single basic nitrogen in 
the side chain seemed to provide sufficient basicity to maintain activity.
95 
 
Figure 2.6. Triazole based antimalarials 
Many hybrid drugs were synthesized by combining 7-chloroquinoline moiety with other 
drugs. The synthesis and antimalarial activities of 1H-1,2,3-triazole tethered 7-
chloroquinoline-Isatin hybrids was shown by Raj and others.  The compound with three 
carbon alkyl chain and chloro substituent at the C-5 position of the isatin ring displayed 
the best activity against cultured W2 strain among the test compounds.
96 
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1,2,3-Triazole tethered β-lactam and 7-chloroquinoline bifunctional hybrids were 
synthesized and evaluated against W2 strain of P. falciparum for their antimalarial 
activities. The activity was found to be dependent on the N-substituent of the β-lactam 
ring and the bis-triazole at the C-3 position, and the p-fluorophenyl substituted analogue 
showed maximum activity. Docking studies via inhibiting P. falciparum dihydofolate 
reductase (PfDHFR) enzyme was made to explain the activity.
97 
Other non-quinoline based antimalarial compounds having 1,2,3-triazole 
pharamacophore were made using click chemistry. Triazole-based β-lactams were 
synthesized and evaluated for their antiplasmodial activity against 3D7, K1, and W2 
strains of Plasmodium falciparum, and KB cells for their cytotoxicity profiles. The 
compound with an N-cyclohexyl substituent in the β-lactam ring and a phenyl group on 
the triazole showed better antiplasmodial activity and cytotoxicity.
98
 
2.8. Triazoles as Pharmacophores, Bioisosters and Linkers 
The importance of triazolic compounds in medicinal chemistry is undeniable. There are 
three main groups of 1,2,3- triazoles: monocyclic, benzotriazoles and 1,2,3-triazolium 
salts. Based on the position of the substituent, the monocyclic 1,2,3- triazoles are 
subdivided into 1H-, 2H- and 4H-1,2,3-triazoles. The 1H- and 2H- forms are tautomers in 
equilibrium both in solution and gas phase. The 1H-1,2,3-triazole acts as both weak base 
(pKa = 1.17) and weak acid (pKa = 9.4), and the ring is not protonated at physiological 
pH.
76, 99 
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The acidity and basicity of nitrogen atoms in 1,2,3-triazoles is explained well by their 
resemblance of having both pyrrole and pyridine-like electronic properties respectively. 
The pyridine-type nitrogen is weakly σ-donating and strongly π-accepting while the five-
membered pyrrole offers an amine-like nitrogen which makes it σ-accepting and π-
donating, causing an aromatic system of π-electron excess.100 
 
Figure 2.7. Electronic structure of 1H-1,2,3-triazole 
The 1,2,3-triazole ring exhibits three resonance forms at which the three N-atoms cause 
the aromatic π-system to be very polarized on a σ-framework. When both resonance and 
inductive effect are assessed, the two C-atoms and the N-atom in the 1-position showed 
positive charges, where as the 2- and 3-Nitrogen atoms indicated partial negative charges. 
The experimental and computational data showed to be consistent indicating a very large 
dipole moment of 4.38 and 4.55 D respectively.
100 
 
Figure 2.8. Structures, tautomerism, partial charges & dipole moments of the 1H-1,2,3-triazole 
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Although the incorporation of 1,2,3-triazoles into pharmacologically active molecules 
had been started decades ago, it became more popular after the introduction of copper-
catalyzed click chemistry. The triazole group not only functiones as a passive linker but 
also as a key part of the pharmacophore. The stabilty to acid-base hydrolysis, oxidative-
reductive conditions and resistance to metabolic degradation make triazoles excellent 
candidates as pharmacophores. Moreover, these heterocycles readily associate with 
biological targets via H-bonding and dipole–dipole interactions.74, 76, 101 
According to the arenology principles, triazoles have been employed to substitute labile 
functional groups such as amides and esters to generate functional, nonclassical 
bioisosteres.
102 
Due to the wide application of peptide chemistry, the bioisosteric 
replacement of amide bonds with triazole ring is becoming an interest. Depending on the 
substituent pattern of the triazole, disubstituted 1,2,3-triazoles can replace either trans- or 
cis-configuration of the amide bond. The presence of both hydrogen bond donor and 
acceptor at similar positions, and closely related dipole moment make 1,2,3-triazloes 
ideal bioisosters for amides.
103 
 
Figure 2.9. Disubstituted trans-amides and 1,2,3-triazoles as bioisosteres
102
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The ability to function as rigid linking units makes 1,2,3-triazoles to be extremely stable 
to hydrolysis and an excellent replacement for amides. Phillips et al. have replaced the 
amide group of Linezolid, an oxazolidinone antibiotic, with a 1,2,3-triazole ring and 
showed the retention of antibacterial activity.
104 
In other similar work, 1,2,3-triazole-
containing novobiocin analogs were designed and synthesized by replacing the amide 
moiety. The analogues exhibited comparable antiproliferative activity when evaluated 
against two breast cancer cell lines.
105 
 
 
Figure 2.10. 1,2,3-Triazoles used as bioisosters of trans-amides
 
The triazole moiety has also been shown to act as a non-classical bioisostere of an ester 
group in arecoline, a muscarinic agonist, for the treatment of Alzheimer’s disease.106 
Because of the basic aromacity of 1,2,3-triazoles, they are suitable isosters of 
heteroaromatic rings. In addition, the triazole moiety is also shown to be the isostere of 
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double bond.
 
In addition to their pharmacophore role, triazoles have been used as 
favorable linkers in the synthesis of dimers and bidentate inhibitors.
107 
In order to address the challenges of high costs associated with high-throughput screening 
and chemical synthesis, Durrant and McCammon developed a novel computer algorithm, 
called AutoClickChem, capable of performing many click chemistry reactions in silico 
that may prove useful in rational drug design and optimization. AutoClickChem, which 
combines virtual screening and click chemistry, is based on the pymolecule toolbox, a 
framework that facilitates the development of future python-based programs requiring 
molecular model manipulation.
108 
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CHAPTER 3: Synthesis of 1,2,3-Triazole-based Antimalarials 
Series of click compounds were synthesized via copper(I)-catalyzed alkyne-azide 
cycloaddition reaction using sodium ascorbate as a reducing agent. Based on previous 
work done in Peyton and other labs, three aliphatic linear chains as linker was considered 
as optimum length both interms of antimalarial activity and hydrophilicity.
63 
3.1. First-Generation Click Compounds 
The azide analogue was prepared in three steps with very good yields as outlined in 
Scheme 3.1. First, the amino-alcohol quinoline (PL16) was synthesized by nucleophilic 
aromatic substitution of commercially available starting material 4,7-dichloroquinoline 
with excess aliphatic chain aminoalcohol. The hydroxyl group was mesylated by 
methane-sulfonyl chloride and triethylamine base to give mesylated-quinoline (PL29).
62
 
Finally, the azide analogue (PL409) was prepared by nucleophilic acidification using 
sodium azide in DMF.
109 
 
Scheme 3.1. Synthesis of starting material – azide analogue 
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The first seven click compounds were synthesized by reacting the azide analogue 
(PL409), which was prepared in large scale, with commercially available terminal 
alkynes to give 1,4-disubstituted-1,2,3-triazoles. The method used by Mahohar et al. was 
adapted by using copper sulfate pentahydrate as catalyst and, two-fold excess of sodium 
ascorbate to reduce the copper (II) to (I).
110
 An equimolar ratio of tert-butanol and water 
was used as mixture of solvents. The reactions were run from room temperature with 
maximum temperature reaching 50
o
C for 3-4 hours to yield the final target compounds in 
moderate yield (26 – 76%). 
 
Scheme 3.2. General synthetic pathway of the first generation click compounds 
Several substituted terminal alkynes were used as the source of various functional groups. 
Tri-substituted terminal alkyne with two aromatic groups and a hydroxyl group was of 
particular interest, due to the similarity with the typical pharmacophore of reversal 
agents. In addition, both ortho- and meta-methoxy substituted click compounds were 
synthesized to make a further structure-activity analysis. In order to evaluate the strength 
of electron-withdrawing groups, monofluoro- and difluoro-substituted click compounds 
were prepared. Finally, one of the carbons at ortho position of the phenyl group was 
replaced by nitrogen and the substituted phenyl groups were replaced by a benzyl group. 
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PL No. Structure of the substituent (R) % yield 
PL404 
 
41 
PL405 
 
72 
PL406 
 
51 
PL407 
 
26 
PL408 
 
76 
PL412 
 
46 
PL414 
 
45 
Table 3.1. The first synthesized click compounds 
3.2. Para-Phenyl Substituted Triazoles 
Based on previous compounds synthesized in the Peyton lab by Bornface Gunsaru et al., 
the para-substituted quinoline analogues showed better activity than their ortho- and 
meta-substituted counterparts.
111
 Various commercially available p-phenyl substituted 
terminal alkynes were used to synthesize 10 click compounds using the same synthetic 
pathway in low to excellent yield (30 – 95%). 
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Scheme 3.3. General synthetic pathway of para-substituted click compounds
 
PL No. Substituent at para position % yield 
PL403 OCF3 30 
PL411 H 50 
PL413 CH3 56 
PL415 NH2 72 
PL416 Br 69 
PL417 OCH3 51 
PL418 Cl 76 
PL419 CF3 68 
PL420 F 84 
PL421 NO2 95 
Table 3.2. Para-substituted click compounds 
In order to perform structure-activity relationship studies, several click compounds 
containing electron-donating and electron-withdrawing groups were synthesized. 
Unsubstituted (H-substituted) analogue was used as a reference. The p-hydroxy phenyl 
substitution was not synthesized because the starting material was not readily available. 
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Three electron-donating containing analogues, including amino-, methoxy- ,and methyl 
were synthesized. In addition, electron-withdrawing groups such as nitro-, 
trifluoromethyl-, and the halogens were prepared for comparison. The halogens used was 
fluorine, chlorine, and bromine (but not iodine). This is because the p-iodo substituted 
terminal alkyne was not commercially available. Finally, a very interesting long-range 
electron withdrawing substituent, trifluoromethoxy group, was prepared to compare with 
the methoxy and trifluoromethyl groups.
112
 
3.3. Triazole with Reversal Agent Pharmacophore 
One additional click compound (PL423) which contains two aromatic rings and nitrogen 
atom between the triazole and the aromatic rings was made to associate the activity with 
the reversal agent pharmacophore.  First the terminal alkyne (PL422) was synthesized 
using the Finkelstein reaction by replacing bromine with a better leaving group, iodine.
113 
The benzhydrylamine was treated by propargyl bromide using catalytic amount of 
sodium iodide in diethyl-ether with minimum heating and fair yield. The synthesized 
terminal alkyne was reacted with the azide analogue (PL409) under the same condition 
with the primarily synthesized click compounds to give PL423 in a good yield. 
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Scheme 3.4. Synthesis of PL423 
The first series of 18 click compounds was assessed for their antimalarial activity, and six 
of them showed better activity than chloroquine against resistant strains of P. falciparum 
(Dd2 and 7G8). Additional compounds containing piperazine ring between the triazole 
and the aromatic rings were planned to be synthesized in order to incorporate a 
protonable nitrogen that possesses a weakly basic character. 
3.4. Para-Phenyl Substituted Terminal Alkynes 
With the intention of making piperazine containing triazoles, 10 para-substituted 
piperazinyl terminal alkynes were prepared. These intermediate molecules were made by 
reacting equimolar ratio of readily available p-substituted piperazines with propargyl 
bromide.
114
 The reaction mixture was refluxed overnight using potassium carbonate as a 
base and acetonitrile as a solvent with moderate to excellent yields. 
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Scheme 3.5. Synthesis of  p-phenyl piperazinyl substituted terminal alkynes 
PL No. Structures (R) % Yield 
PL428 
 
 
32 
PL429 
 
87 
PL430 
 
98 
PL431 
 
70 
PL432 
 
95 
PL433 
 
69 
PL434 
 
57 
PL435 
 
67 
PL436 
 
86 
PL437 
 
94 
Table 3.3. Structures of 10 piperazine-containing terminal alkynes 
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3.5. Piperazinyl-linked Triazoles 
The p-substituted piperazines were selected based on different functional groups, 
heteroatomic replacement, linker length between the piperazine and the aromatic ring, 
and multiple substitution. The cyclohexyl piperazine was selected for comparison of the 
aliphatic cyclic compound with the phenyl-substituted piperazine. Consequently, nine 
very interesting piperazinyl containing triazoles were synthesized using CuAAC. 
The concentrations of the copper sulphate catalyst and reducing agent sodium ascorbate 
were reduced by half from the previous method. This was because of the difficulty in 
solubility encountered during the work-up (liquid-liquid extraction) and  purification 
(recrystallization) processes of the first series of synthesized molecules.
96, 114
 The 
increased reaction time was the cost of reducing the catalyst and reducing agent 
concentrations which increased from 3-4 hours to 1-2 days. The amount of tert-butanol 
solvent used was also increased to threefold of the water co-solvent with moderately 
heating the reaction to 50
o 
C. 
 
Scheme 3.6. Synthesis of piperazine containing triazoles 
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The triazole-based synthesized compounds contain both electron-donating (methyl, 
methoxy, and hydroxyl) and electron-withdrawing (trifluoromethyl, chloro, and 
dichloro). The carbon atom at the ortho position of the phenyl group was mono- and di-
substituted by nitrogen to give 2-pyridyl and 2,6-pyrimidyl substituted triazoles.  
PL No. Structures (R) % Yield 
PL440 
 
69 
PL441 
 
52 
PL442 
 
35 
PL443 
 
61 
PL444 
 
76 
PL445 
 
70 
PL446 
 
68 
PL447 
 
80 
PL448 
 
77 
Table 3.4. Structures of piperazinyl-triazoles 
The p-trifluoromethyl substituent was made with one aliphatic linker between the 
piperazine and the aromatic ring. The unsubstituted (H-substituted) phenyl analogue was 
considered as an optimum reference between electron-donating and withdrawing groups. 
The di-chloro substituted triazole was also synthesized to notice the change it brings in 
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the strengh of the electron-withdrawing capacity of the ring. The click compound 
containing cyclohexyl substituent was not successful in synthesizing. 
3.6. Triazole-based Bisquinoline Antimalarial 
 
Scheme 3.7. Synthesis of bisquinoline containing triazole 
As the potent antimalarial activity of bisquinolines was observed in the previously 
synthesized compounds in Peyton lab, bisquinoline containing 1,2,3-triazole ring was 
synthesized by copper catalyzed click chemistry (Scheme 3.7). 
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The target bisquinoline was synthesized in three steps with moderate to very good yields. 
4-piperazinyl-quinoline (PL49) was first synthesized by refluxing commercially available 
starting material 4,7-dichloroquinoline with anhydrous piperazine in ethanol.
115 
The 
terminal alkyne analogue (PL467) was then prepared by reacting PL49 with propargyl 
bromide using potassium carbonate as a base and acetonitrile as solvent.
114
 Finally, the 
target bisquinoline triazole (PL456) was made by copper catalysed click reaction in 
optimum catalytic concentration and reaction time than previous click reactions. 
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CHAPTER 4: Structure-Activity Relationship of Triazoles-Based Antimalarials 
The efficiency of synthesizing several triazole-based antimalarials have proven click 
chemistry to be a fast and efficient route. Antimalarial click compounds were synthesized 
using copper(I)-catalyzed azide-alkyne cycloaddition reactions and tested for their in 
vitro activity against D6, Dd2, and 7G8 strains of Plasmodium falciparum. Several of 
them have shown better activity against chloroquine-resistant strains (Dd2 and 7G8) than 
chloroquine.   
4.1. The first generation click compounds 
The first generation click compounds synthesized in Peyton lab contain the triazole ring 
connected directly to one or two aromatic rings with different substitutions. Six of the 
triazole-based click compunds showed better activity against chloroquine resistant, Dd2 
and 7G8, strains of P. falciparum.  
Structure-activity relationship studies were made on the synthesized compounds. The 
phenyl-substituted triazole (PL411) showed an enhanced activity when compared to the 
2-pyridyl substituted triazole (PL412) against all the three strains.  PL411 gave a better 
IC50 values of 76.8, 87.5 and 151 nM when compared to 420, 960, and 590 nM (d6, Dd2, 
and 7G8 strains respectively) of PL412. 
In another comparison, PL411 showed decreased activity which compared to PL414 
which has an additional methyl linker between the phenyl and the triazole rings. Thus 
addition of a methyl linker was found to be an advantage over direct connection in this 
case. 
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Figure 4.1. The effect of hetroatomic replacement and linker addition 
PL No. Number of 
linker (n) 
Type of  
atom (Y) 
IC50 (nM) 
D6 Dd2 7G8 
PL411 0 C 76.8 87.5 151 
PL412 0 N 423 696 592 
PL414 1 C 9.6 77.7 85.8 
Table 4.1. The IC50 comparison of phenyl, 2-pyridyl, and benzyl triazoles 
The effect of ortho-, meta-, and para-substitutions were also investigated by comparing 
the electron-donating methoxy group on the phenyl directly connected to the triazole 
ring. The para-methoxy substituted triazole (PL417) showed an enhanced activity when 
compared to the meta-substituted (PL406), which inturn also showed a better activity 
than the ortho-substituted triazole (PL405) against all the three strains.  
 
Figure 4.2. The effect of methoxy group substitution 
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PL No. Position of methoxy 
substituent  
IC50 (nM) 
D6 Dd2 7G8 
PL405 ortho- 98.6 209.8 192.4 
PL406 meta- 52.4 120 122.3 
PL417 para- 40.5 108.8 140.1 
Table 4.2. The IC50 comparison of ortho-, meta-, and para-methoxy substitutions 
The electron-withdrawing strength effect of halogens were compared by mono- and di-
fluorinated substitutions on the phenyl ring directly attached to the triazole. It was found 
that double halogen (fluorine) substitution (PL408) had improved activity by, almost 2.5 
times, for both D6 and Dd2 strains, when compared to mono-fluoro substitution (PL407). 
                 
               PL407 (81
D6
, 109
Dd2
, 129
7G8
)                     PL408 (23
D6
, 39
Dd2
, 96
7G8
) 
 
Figure 4.3. The effect of mono- and di-fluoro substitution 
 
The long-range electro-withdrawing group, the trifluoromethoxy-substituted triazole 
(PL403) showed the highest activity among all the 18 synthesized first generation 
triazoles. It showed about 4 times better activity than chloroquine against both CQ-
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resistant strains. The IC50 values of PL403 are 12.8 and 14.5 nM, while CQ has 54 and 63 
for Dd2 and 7G8 strains of P. falciparum respectively. 
When the para-methoxy substituted triazole (PL417) was compared with PL403, the 
latter showed a superior activity. The replacement of hydrogen atoms by the most 
electronegative element fluorine presented an 8 times increase in activity. Moreover, 
PL403 indicated about 2.5 times increase in activity for Dd2 strain, when compared with 
a similar electron-withdrawing substituent, trifluoromethyl-substituted triazole (PL419). 
                 
PL417 (41
D6
, 109
Dd2
, 140
7G8
)        PL403 (10
D6
, 13
Dd2
, 15
7G8
)       PL419 (11
D6
, 32
Dd2
, 19
7G8
) 
Figure 4.4. Comparison of the IC50 values of para-methoxy, trifluoromethoxy and 
Trifluoromethyl-phenyl substituted click compounds 
 
 
The electron-donating substituents showed inferior activities than chloroquine. These 
include the para-phenyl substitutions of methyl (PL413), amino (PL415), and methoxy 
(PL417) functional groups. While the para-methyl substituted triazole presented the best 
activity from the three electron donating groups, the para-amino showed the least activity 
against all CQ-sensitive and CQ-resistant strains of P. falciparum. 
However, the electron-withdrawing groups such as the trifluoromethyl, nitro and the 
halogens presented better or comparable activity than chloroquine. Most of them 
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exhibited an improved IC50 values than CQ against both resistant strains except the para-
fluoro substituted triazole (PL420). 
                
              PL419 (11
D6
, 32
Dd2
, 19
7G8
)                      PL421 (19
D6
, 51
Dd2
, 45
7G8
) 
Figure 4.5. The IC50 values of para-phenyl substituted electron-withdrawing groups 
 
When the halogens are compared, the para-bromophenyl substituted triazole (PL416) 
showed the best activity against Dd2 strain of P. falciparum (IC50 of 30.7 nM). The 
chloro-substituted (PL418) exhibited enhanced activity against both D6 and 7G8 strains 
(IC50 of 18.8 and 36.6 nM respectively) than PL416 and the fluoro-substituted triazole 
(PL420). The general trend for the halogens indicated that the antimalarial activity 
increases when electronegativity of the substituent atom decreases. 
 
  PL416 (423
D6
, 31
Dd2
, 50
7G8
)         PL418 (19
D6
, 43
Dd2
, 37
7G8
)          PL420 (40
D6
, 85
Dd2
, 80
7G8
) 
Figure 4.6. The IC50 values comparison of para-halogen substituted triazoles 
When all the para-phenyl substituted electron-withdrawing groups are compared, the 
trifluoromethyl and the chloro substitutions showed potent activities, with trifluoromethyl 
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group possessing the highest. The bromo and nitro groups at para position of the phenyl 
ring indicated moderate activities, with the bromo group retaining the maximum activity 
of all against Dd2 strain of P. falciparum. The least leaving group, fluorine-substitution, 
showed the minimum activity of all electron-withdrawing groups.  
Strains of Plasmodium falciparum Electron-withdrawing group 
D6 Br < F < NO2 = Cl < CF3 
Dd2 F < NO2 < Cl < CF3 < Br 
7G8 F < Br < NO2 < Cl < CF3 
Table 4.3. Comparison of various electron-withdrawing groups 
Surprisingly, the two click compounds that contain two aromatic groups resembling the 
RA pharmacophore showed poor antimalarial activity. The first compound (PL404) 
which has a tetra-substituted carbon connecting the triazole ring with two aromatic rings 
and hydroxyl group, showed better activity only against 7G8 strain of P. falciparum. The 
second click compound (PL423) containing a secondary amine between the triazole and 
two aromatic rings showed poor antimalarial activity against all the strains. 
          
PL404 (25D6, 82Dd2, 487G8)                          PL423 (80D6, 160Dd2, 1897G8) 
Figure 4.7. Click compounds containing pharmacophore similar to the reversal agent 
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Out of the 18 synthesized first generation click compounds, six were found to be more 
active than chloroquine against CQ-resistant strains of P. falciparum. Although none 
showed better activity against the CQ-sensitive (D6) strain, the trifluoromethoxy (PL403) 
and trifluoromethyl (PL419) substituted triazoles showed comparable activity with 
chloroquine (IC50 values of 10.4 and 11 nM respectively). 
All six selected compounds have exhibited better activity against Dd2 strain of P. 
falciparum than chloroquine. For the 7G8 strain, five showed an enhanced activity than 
CQ except the difluoro-phenyl substituted triazole (PL408), which has an IC50 value of 
95.7 nM when compared to 57 nM of CQ (Refer to Table 4.4). 
In conclusion, electron-withdrawing (PL416, PL418, PL419, and PL421) and long-range 
electron-withdrawing (PL403) substitutions at para positions, and double electron with-
drawing (PL408) substitutions were found to be an advantage to have a better 
antimalarial activity for these group of click compounds. 
4.2. Piperazinyl-linked click compounds 
“Second generation” of triazole antimalarials were synthesized by incorporating 
piperazine ring between the triazole and the para-substituted phenyl ring, to yield a 
protonable nitrogen in the linker which increases the basicity of the molecule. When 
compared to the first synthesized click compounds, these 9 compounds generally showed 
enhanced antimalarial activity against all the strains of P. falciparum. 
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PL No. Structures IC50 Values 
D6 Dd2 7G8 
CQ Chloroquine 5.9 
 
54 57 
PL403 
 
10.4 12.8 14.5 
PL408 
 
22.7 39.1 95.7 
PL416 
 
423 30.7 49.6 
PL418 
 
18.8 42.7 36.6 
PL419 
 
11 31.6 18.7 
PL421 
 
18.8 50.5 44.5 
Table 4.4. Selected first generation click compounds with better activity than CQ 
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The para-substituted electro-donating groups generally demonstrated better activities than 
CQ and the first generation triazoles with similar substituents. The para-methyl (PL442) 
and para-methoxy (PL444) substituted triazoles exhibited an improved activity against 
Dd2 and 7G8 strains of P. falciparum than did CQ. However, the para-hydroxy 
substituted triazole (PL446) showed poor activity against all the 3 strains of P. 
falciparum. 
 
            PL442 (12
D6
, 37
Dd2
, 18
7G8
)                                   PL444 (33
D6
, 68
Dd2
, 65
7G8
) 
 
PL446 (155
D6
, 94
Dd2
, >250
7G8
)     
Figure 4.8. The activity of electron-donating groups substituted at the para position 
The 2-pyridyl (PL443) and 2,6-pyrimidyl (PL440) Piperizenyl-substituted triazoles gave 
poor activity against all the three strains of P. falciparum when compared to CQ, with 
PL440 presenting the lowest activity of all the synthesized triazoles. 
As the effect of double substitution of electron-withdrawing groups was shown to 
improve the antimalarial activity in the first series of compounds using fluorine; the same 
result was obtained with the piperazinyl-linked triazoles. When the dichloro-substituted 
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(PL448) was compared with monochloro-substituted (PL447) phenyl-piperazinyl triazole, 
the former showing about 1.6 times increased activity against all the three stains. 
   
          PL447 (8.8
D6
, 26.5
Dd2
, 19
7G8
)                          PL448 (6.8
D6
, 15.2
Dd2
, 11
7G8
) 
Figure 4.9. The comparison of IC50 values of mono and dichloro-substituted triazoles 
The addition of a single methyl linker between the piperazine and the phenyl ring have 
shown to retain the antimalarial activity against all the three strains of P. falciparum 
when the phenyl ring was para-substituted by a trifluoromethyl group. 
     
Figure 4.10. Triazole having methyl linker between piperazine and phenyl rings 
Improved antimalarial activity was observed when the first series of triazoles were 
compared with piperazine linked for the same substituents. This increase in activity is 
attributed to the integration of the piperazine linker, which provides additional proton for 
this second generation click triazoles. 
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Figure 4.11. The comparison of the selected first and second generation triazoles for                
similar substituents 
When the electron-donating substituents, methyl and methoxy, were compared, PL442 
and PL444 indicated more potency than their respective piperazine omitted counterparts 
PL413 and PL417 against D6, Dd2 and 7G8 strains. Moreover, PL447, which has an 
electron-withdrawing chloro-substituent, indicated two-fold activity when compared to 
PL418. The same trend was observed for the unsubstituted (H-substituted) triazoles 
against all the three strains (PL411 vs PL445). 
In summary, six of the nine synthesized piperazinyl-linked triazoles were found to have 
more potent activity than chloroquine against CQ-resistant strains of P. falciparum. 
Although none of them showed better activity against CQ-sensitive strain, the para-chloro 
(PL447) and dichloro (PL448) substituted click compounds exhibited comparable activity 
with chloroquine with an IC50 values of 8.8 and 6.8 nM respectively (Refer to table 4.5). 
R = CH3,       PL413 (41
D6
, 61
Dd2
, 60
7G8
)                 PL442 (12
D6
, 37
Dd2
, 18
7G8
) 
R = CH3O,    PL417 (41
D6
, 109
Dd2
, 140
7G8
)             PL444 (33
D6
, 68
Dd2
, 65
7G8
) 
R = H,           PL411 (77
D6
, 88
Dd2
, 151
7G8
)               PL445 (17
D6
, 67
Dd2
, 74
7G8
) 
R = Cl,          PL418 (19
D6
, 43
Dd2
, 37
7G8
)                 PL447 (8.8
D6
, 26.5
Dd2
, 19
7G8
) 
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PL No. Structures IC50 Values 
D6 Dd2 7G8 
CQ 
 
5 
 
69 47 
PL441 
 
10 40 16 
PL442 
 
12 37 18 
PL444 
 
33 68 65 
PL445 
 
17 67 74 
PL447 
 
8.8 26.5 19 
PL448 
 
6.8 15.2 11 
Table 4.5. Selected piperazine containing click compounds having better activity than    
Chloroquine against CQ-resistant strains 
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All the six selected compounds possessed better potency against Dd2 strain of P. 
falciparum than chloroquine. When tested against 7G8 strain, PL441, PL442, PL447 and 
PL448 showed enhanced activity but not the para-methoxy (PL444) and the unsubstituted 
(PL445) triazoles. Generally, the para and di-substitutions with electron-withdrawing 
groups were found to be beneficial for having better antimalarial activity for these types 
of piperazine-linked click compounds. PL448 has proved to possess the best activity from 
all the second generation triazoles. 
4.3. The Activity of Triazole-based Bisquinoline 
The triazole-based bisquinoline, PL456, synthesized by linking two chloroquinoline 
moieties by triazole ring, was tested for  in vitro antimalarial activity against all the three 
strains of P. falciparum. Unlike the other click compounds, it showed excellent activity 
against CQ-sensitive strain (D6). In addition, PL456 exhibited a potent activity against 
both CQ-resistant strains (Dd2 and 7G8) when compared to chloroquine. 
 
Compounds IC50 (nM) 
D6 Dd2 7G8 
Chloroquine 9 143 127 
PL456 0.5 10 11 
Table 4.6. The structure and activity of triazole-based bisquinoline 
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CHAPTER 5: Reversed Chloroquines 
5.1. The 6-Aminoquinoline antimalarials 
Although the 4- and 8-quinoline substitutions are very common on the quinoline ring, 
there are few antimalarials containing functional groups on the 6-position. An electron-
donating, methoxy group, is a very common substituent on the 6-position of the quinoline 
ring. Common antimalarial drugs such as quinine and primaquine all have a methoxy 
functional group substitution on the 6-position but the main linkers are on the 4- and 8-
quinoline substitutions respectively. 
 
Scheme 5.1. Synthesis of 6-aminoquinoline antimalarial, PL370 
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A reversed quinoline hybrid molecule was synthesized in Peyton lab by linking 6-
quinoline moiety with benzhydryl-piperazine which has the reversal agent 
pharmacophore. First, PL323 was prepared by treating 6-aminoquinoline with 3-
chloropropionyl-chloride in a cold reaction using triethylamine as a base and 
dichloromethane as a solvent.
116
 The amide was reacted with benzhydryl-piperazine to 
form PL369, which is further reduced using LiAlH4 in cold reaction to get the target 
molecule, PL370 in a good yield. 
When tested for antimalarial activity against D6, Dd2 and 7G8 strains of P. falciparum, 
PL370 showed poor antimalarial activty against both CQ-sensitive and CQ-resistant 
strains with an IC50 value of  >250 nm when compared to chloroquine.  
5.2. Fluoxetine as Reversal Agent 
Among the common reversal agents,  the SSRI antidepresant, fluoxetine which doesn’t 
possess any intrinsic antimalarial activity when used alone, showed to potentiate the 
effect of chloroquine. Fluoxetine showed to modulate chloroquine resistance of CQ-
resistant W2 clone by 66% at a concentrations of 500 nM with verapamil showing only 
61%.
54  
In other recent studies,  fluoxetine showed to reverse both chloroquine and 
mefloquine resistance
 
against Dd2 strain of P. falciparum although it indicated to be 
more synergistic with chloroquine than mefloquine.
117
 
In addition, fluoxetine has proven to be a highly effective chemosensitizer in multidrug 
resistance (MDR) for cancer chemotherapy. In vitro, fluoxetine enhanced 10-100 fold 
cytotoxicity of many anticancer drugs in drug-resistant cells by increasing drug 
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accumulation within MDR-cells and inhibiting drug efflux from those cells. In vivo, 
fluoxetine enhanced 12-fold accumulation of doxorubicin within tumors with unaltered 
pharmacokinetics.
118
 
In other in vitro and in vivo findings,  fluoxetine was found to be a chemosensitizer of the 
multipump type and considered as a fourth-generation chemosensitizer.
119 
Considering 
the effect of fluoxetine as a better chemosentisizer, reversed chloroquine molecule using 
fluoxetine as a reversal agent was synthesized in Peyton lab.  
The free-base was reacted with PL29 using triethylamine as a base in tetrahydrofuran to 
give PL410 in moderate yield. The molecule was potent antimalarial and showed about 
20-fold activity when compared to chloroquine. It has an IC50 values of < 2.5 nm for Dd2 
and 7G8 strains of P. falciparum while CQ has 54 and 57 nM respectively.  
 
Scheme 5.2. Synthesis of reversed chloroquine using fluoxetine as reversal agent 
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5.3. Meta-substituted Analogue of PL69 
The first hit compound, PL01 which was synthesized as a hybrid drug by using 
haloquinoline moiety and imipramine as a reversal agent was optimized to increase its 
hydrophilicity. PL69 was the result of lead optimization that is both potent antimalarial 
and has better hydrophilicity than the first analogue. In order to see the effect of a 
substituent on the activity, PL425, which has the nitrogens on the meta positions of the 
aromatic rings of the reversal agent instead of on the ortho positions was synthesized. 
First, 1,8-Diazafluoren-9-one (DFO) was reacted with protected piperidine (Ethyl-4-
amino-1-piperidine carboxylate) by using catalytic amount of p-toluenesulfonic acid to  
 
Scheme 5.3. Synthesis of m-substituted analogue of PL69 
form PL460 in an excellent yield.  The piperidine was deprotected in basic condition by 
treating with NaOH in ethanol to prepare the intermediate product PL424. Finally, the 
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reversal agent was reacted with PL29 using potassium carbonate base to give the target 
compound, PL425 in a good yield. 
The meta-substituted compound showed better antimalarial activity than CQ, only against 
Dd2 strain of P. falciparum with an IC50 value 32.5 nM when compared to 54 nM of 
chloroquine. However, for the D6 and 7G8 strains, PL425 was found to be less active 
than CQ. 
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CHAPTER 6: Summary and Conclusion 
Malaria is considered as one of the most prevalent and debilitating diseases affecting 
humans. There are 3.4 billion people at risk of malaria transmission with more than half a 
million deaths,  many of them are children. Plasmodium falciparum is the most virulent 
form  and responsible for about 80% of human malaria worldwide. The plasmodium 
parasite developed resistance to  several antimalarial drugs.  
Chloroquine is one of the most successful antimalarials developed that is effective, cheap, 
and safe to children and pregnant women. However, due to the emergence of drug 
resistance by P. falciparum, its use has been limited. In order to circumvent chloroquine 
resistance, reversed chloroquines that reverse the resistance by inhibiting the efflux of 
chloroquine were designed in Peyton lab. These hydrid drugs has been found to be potent 
against both chloroquine-sensitive and resistant strains of P. falciparum both in vitro and 
in vivo. 
It’s a challenging task for medicinal chemists to develop new patentable drugs with 
strong activity and good pharmacokinetic properties in short time. Click chemistry has 
shown to have a cutting-edge advantage in demanding world of medicinal chemistry in 
hit finding and lead optimization due to its reliance on extremely quick reactions. 
Particularly, the copper(I)-catalyzed cycloaddition reaction between azides and terminal 
alkynes to give 1,4-disubstituted-1,2,3-triazoles has become the benchmark of ‘click 
chemistry’ by its reliability, selectivity and biocompatibility. 
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The incorporation of 1,2,3-Triazoles into pharmacologically active molecules became 
more popular after the introduction of copper-catalyzed click chemistry. The stabilty to 
acid-base hydrolysis, oxidative-reductive conditions and metabolic degradation make 
triazoles not only good passive linkers but also excellent candidates as pharmacophores 
and bioisosters. Moreover, these heterocycles readily associate with biological targets via 
H-bonding and dipole–dipole interactions. 
Series of click compounds were synthesized via copper(I)-catalyzed alkyne-azide 
cycloaddition reaction by modifying the aliphatic chains terminal of chloroquine. Three 
aliphatic linear chains as linker between the chloroquinoline and the triazole rings were 
chosen as optimum length both interms of antimalarial activity and hydrophilicity. The 
28 antimalarial click compounds were tested for their in vitro activity against D6, Dd2, 
and 7G8 strains of P. falciparum. 
The first 18 click compounds was synthesized by reacting the azide analogue with 
commercially available terminal alkynes. The first generation click compounds 
synthesized contain the triazole ring connected directly to one or two aromatic rings with 
different substitutions. Six of the triazole-based click compunds showed better activity 
against chloroquine resistant, Dd2 and 7G8, strains of P. falciparum.  Particularly, PL403 
showed about 4 times better activity than chloroquine with an IC50 values of 12.8 and 
14.5 nM against CQ-resistant Dd2 and 7G8 strains respectively. 
The second generation triazole antimalarials were synthesized by incorporating 
piperazine ring between the triazole and the p-substituted phenyl ring to have a 
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protonable nitrogen which increases the basicity of the molecule. The modification has 
brought an enhanced antimalarial activity when compared to the first series of 
compounds. Six of the nine synthesized piperazinyl-linked triazoles were found to have 
potent activity than chloroquine against CQ-resistant strains. The dichloro substituted 
triazole, PL448, has proved to possess an excellent activity with IC50 values of 15.2 
(Dd2) and 11 (7G8) nM.  
In addition to click compounds, other reversed chloroquines were synthesized. A 
reversed quinoline hybrid molecule was synthesized by linking 6-quinoline moiety with 
benzhydryl-piperazine as a reversal agent. When tested for antimalarial activity, PL370 
showed poor antimalarial activity against all strains of P. falciparum. By considering the 
effect of an SSRI antidepressant, fluoxetine (Prozac), as a very good chemosentisizer in 
reversing both chloroquine and mefloquine resistance,  PL410 was synthesized. This hit 
was found to be about 20-fold potent than chloroquine with IC50 values of < 2.5 nM for 
Dd2 and 7G8 strains of P. falciparum.  
In conclusion, the efficiency of synthesizing several triazole-based antimalarials have 
proven click chemistry to be fast and efficient reaction. Several of the synthesized 
triazole-based antimalarials possessed better activity against chloroquine resistant strains 
than chloroquine. Generally, para-substitutions and di-substitutions with short-range and 
long-range electron-withdrawing groups were found to be beneficial for having better 
antimalarial activity for these group of click compounds. 
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CHAPTER 7: Experimental Materials and Methods 
7.1. Instrumentation 
All starting chemicals were purchased from Sigma-Aldrich Chemical Co. and TCI 
America. Nomenclature was done using ChemBioDraw Ultra. Thin layer 
chromatography was mostly done on Alumina basic column using ethyl-acetate:methanol 
(90:10) as mobile phase and visualized by UV lamp (254 nm). The purification was 
commonly done by CombiFlash
®
 Rf-200 chromatography using silica column at UV 
absorbance of 254 and 280 nM with solid loading, and collecting only the peaks. The 
eluents used are chloroform:methanol (90:10) for target compunds and hexane:ethyl-
acetate for intermediate compounds.   
The compounds were characterized by NMR and Mass spectroscopy. 
1
H-, 
13
C-, COSY, 
HSQC, HMBC and NOESY experiments were run on Bruker 400 MHz instrument, using 
the standard pulse sequences provided at 25
0
C. High resolution mass spectrometry was 
performed on Bruker micrOTOF-Q instrument. Results were obtained using electospray 
ionization (ESI) in the positive mode, at a flow rate of 0.4 mL/min with methanol or 
acetonitrile. 
7.2. General Synthetic Procedures 
PL16 (3-((7-chloroquinolin-4-yl)amino)propan-1-ol) 
Purified 4,7-dichloroquinoline (1eq, 5 g, 25.2 mmol) and 3-amino-1-propanol (12.3 eq, 
23.7 ml, 309.9 mmol) was healted slowly for 1 hour at 70
o 
C and the temperature was 
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increased to 135
o
 C and stirred for 7 additional hours. After the completion was 
confirmed by TLC, the reaction mixture was poured to ice-cold H2O (100ml). The white 
precipitate formed was filtered by vaccum filtration, washed with water and dried. After 
drying, the solid was recrystallized using EtOAC (50ml). The solution was filtered, and 
after cooling down, vaccum-filtered and washed with water to give pure, white-yellowish 
solid (5.02 g, 84%). 
1
H NMR (400 MHz, DMSO-d6) δ 8.39 (d, J = 5.5 Hz, 1H), 8.25 (d, J 
= 9.0 Hz, 1H), 7.78 (d, J = 2.2 Hz, 1H), 7.44 (dd, J = 9.0, 2.3 Hz, 1H), 7.30 (t, J = 5.4 Hz, 
1H), 6.48 (d, J = 5.4 Hz, 1H), 3.55 (t, J = 6.2 Hz, 2H), 3.39 – 3.28 (m, 7H), 1.88 – 1.76 
(m, 2H). 
PL28 (2-((7-chloroquinolin-4-yl)amino)ethan-1-ol) 
A mixture of purified 4,7-dichloroquinoline (1 eq,  5 g, 25.25 mmol) and ethanolamine 
(10 eq, 15.24 ml,  252.5 mmol) was heated with stirring overnight at 130 
o
C. After the 
reaction mixture was cooled to RT, it was poured to pre-cooled water (150 ml). The 
white precipitate formed was filtered and dried. After drying, the solid was recrystallized 
by methanol (100 ml), cooled in ice and filtered by vaccum-filtration to give a pure white 
solid (4.48 g, 80 %). 
1
H NMR (600 MHz, DMSO-d6) δ 8.39 (d, J = 5.4 Hz, 1H), 8.27 (d, 
J = 9.0 Hz, 1H), 7.79 (d, J = 2.3 Hz, 1H), 7.45 (dd, J = 9.0, 2.4 Hz, 1H), 7.27 (t, J = 5.6 
Hz, 1H), 6.50 (d, J = 5.5 Hz, 1H), 3.67 (t, J = 6.1 Hz, 2H),  3.36 (q, J = 5.8 Hz, 2H).  
PL29 (3-((7-chloroquinolin-4-yl)amino)propyl methanesulfonate) 
To a suspension of PL16 (1 eq, 5 g, 21.2 mmol) in anhydrous THF (100ml) stirring under 
N2 and cooled in an ice-bath, triethylamine (2 eq, 5.9 ml, 42.3 mmol) was added. After 
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the mixture was cooled to 0 
o
C, methane-sulfonyl chloride (1.3 eq, 2.13 ml, 27.6 mmol) 
was added very slowly keeping the temperature below 10 
o
C and the reaction was stirred 
for 1 hour. After the completion was confirmed by TLC, work-up was done by liquid-
liquid extraction by adding saturated NaHCO3 (100ml). After separating the organic 
layer, the aqueous layer was extracted with diethyl-ether (200ml and then 2*100ml). The 
orgainic layers were mixed and dried by anhydrous MgSO4, concentrated by rotovap and 
dried to give white-yellowish solid (5.4 g, 82%). 
1
H NMR (400 MHz, DMSO-d6) δ 8.43 
(d, J = 5.3 Hz, 1H), 8.28 (d, J = 9.0 Hz, 1H), 7.82 (d, J = 2.2 Hz, 1H), 7.48 (dd, J = 9.0, 
2.3 Hz, 1H), 7.36 (t, J = 5.5 Hz, 1H), 6.52 (d, J = 5.4 Hz, 1H), 4.37 (t, J = 6.2 Hz, 2H), 
3.51 – 3.33 (m, 2H), 3.21 (s, 3H), 2.10 (p, J = 6.5 Hz, 2H).  
PL30 (2-((7-chloroquinolin-4-yl)amino)ethyl methanesulfonate) 
PL28 (1 eq, 5 g, 22.5 mmol) was dissolved in dry acetone (100 ml) and triethylamine (1.5 
eq, 4.7 ml, 33.7 mmol) was added. The mixture was chilled to 0 
o
C in an ice-bath and the 
reaction was carried under N2. Methane-sulfonylchloride (1.2 eq, 2.1 ml, 27 mmol) was 
added drop-wise keeping the temperature below 10 
o
C. The reaction was continued to run 
with stirring for 5 hours. After the completion, the solid was filtered and the solvent was 
evaporated. The two solids were combined and washed by saturated NaHCO3 (100ml). 
The orgainic layer was dried by anhydrous MgSO4, filtered and concentrated to give 
white solid (5.8 g, 85%). 
1
H NMR (400 MHz, DMSO-d6) δ 8.44 (d, J = 5.4 Hz, 1H), 8.26 
(d, J = 9.0 Hz, 1H), 7.85 – 7.76 (m, 1H), 7.55 – 7.43 (m, 2H), 6.60 (d, J = 5.5 Hz, 1H), 
4.44 (t, J = 5.4 Hz, 2H), 3.68 (q, J = 5.4 Hz, 2H), 3.17 (s, 3H). 
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PL49 (7-chloro-4-(piperazin-1-yl)quinoline) 
4,7-dichloroquinline (1 eq, 2.5 g, 12.62 mmol) and anhydrous piperazine (7 eq, 7.6 g, 
88.36 mmol) were refluxed in ethanol (37.5 ml) for 12 hours. After completion, the 
solvent was evaporated and the solid was dissolved in dichloromethane (50 ml). The 
solution was washed with saturated NaHCO3 (4 * 25 ml). Finally the organic layer was 
separated, dried by anhydrous MgSO4, filtered and concentrated. The compound was pure 
enough to be used in the next step without purification (2.62 g, 84 %). 
1
H NMR (400 
MHz, CDCl3) δ 8.72 (d, J = 5.0 Hz, 1H), 8.03 (d, J = 2.1 Hz, 1H), 7.95 (d, J = 8.9 Hz, 
1H), 7.42 (dd, J = 9.0, 2.1 Hz, 1H), 6.83 (d, J = 5.0 Hz, 1H), 3.23 – 3.12 (m, 9H), 1.79 (s, 
1H, NH). 
PL107 (N
1
-(7-chloroquinolin-4-yl)propane-1,3-diamine) 
4,7-dichloroquinoline (1 eq, 2.3 g, 11.61 mmols) and 1,3-diaminopropane (4.4 eq, 4.27 
ml, 51.1 mmols) were stirred neatly for 1.5 hours at 80 
o
C and 6 hours at 145 
o
C. After 
the completion of the reaction was confirmed by TLC, it was cooled to room temperature. 
NaOH (10%, 7.2 ml) was added and the mixture was stirred on a sonicator. The 
precipitate was filtered by vaccum-filtration and washed with excess water and dried to 
give white solid (2.5 g, 91 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.38 (t, J = 5.3 Hz, 1H), 
8.27 (dd, J = 21.6, 9.1 Hz, 1H), 7.78 (d, J = 2.3 Hz, 1H), 7.44 (ddd, J = 8.8, 6.1, 2.3 Hz, 
1H), 6.49 (dd, J = 16.2, 5.4 Hz, 1H), 3.43 (q, J = 6.4 Hz, 1H), 3.33 (t, J = 6.9 Hz, 2H), 
3.07 (s, 2H), 2.70 (t, J = 6.5 Hz, 2H), 1.75 (p, J = 6.7 Hz, 2H). 
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PL190 (N-(piperidin-4-yl)-1,1-di(pyridin-2-yl)methanimine) 
2, 2’-dipyridyl-ketone (1 eq, 3.0 g, 16.3 mmol) was dissolved in toluene (70 ml). 4-
aminopiperidine (1.15 eq, 1.98 ml, 18.7 mmol) was added, followed by p-
toluenesulfonic-acid (0.1 g). The reaction was refluxed while stirring and using dean-
stark apparatus to continuously remove the water by-product. After the completion of the 
reaction, the solvent was evaporated and purified by combi-flash chromatography on 
silica column (1.27 g, 29 %). 
1
H NMR (400 MHz, Chloroform-d) δ 8.72 (dt, J = 5.0, 1.3 
Hz, 1H), 8.55 – 8.46 (m, 1H), 8.15 (dt, J = 8.0, 1.2 Hz, 1H), 7.77 (dtd, J = 26.2, 7.8, 1.8 
Hz, 2H), 7.38 – 7.09 (m, 3H), 3.39 (tt, J = 9.4, 4.5 Hz, 1H), 3.18 – 3.02 (m, 2H), 2.79 – 
2.48 (m, 2H), 1.87 – 1.65 (m, 4H). 
PL294 (7-chloro-N-(piperidin-4-yl)quinolin-4-amine) 
4,7-dichloroquinoline (1 eq, 5 g, 25 mmol) and 4-aminopiperidine (5 eq, 13.4 ml, 126 
mmol) in N,N-diisopropylethylamine (100 ml) was heated at 100 
o
C for 20 hours. The 
DIPEA was evaporated and the crude was purified by combi-flash chromatography in 
silica column and using DCM:MeOH:Et3N (8.9:1:0.1) as eluents to give a pure solid 
(3.10 g, 47 %). 
1
H NMR (400 MHz, CDCl3):  δ 8.62 (d, J = 5.2, 1H), 7.96 (d, J = 2.0, 
1H), 7.85 (d, J = 8.9, 1H), 7.35 (dd, J = 8.9, 2.0, 1H), 6.75 (d, J = 5.2, 1H), 5.24 (s, 1H), 
3.48 (d, J = 12.0, 2H), 2.89 (m, 1H), 2.82 (t, J = 11.6, 2H), 1.97 (d, J = 12.0, 2H), 1.61 
(m, 4H). 
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PL323 (3-chloro-N-(quinolin-6-yl)propanamide) 
6-aminoquinoline (1 eq, 5.0 g, 34.68 mmol) and triethylamine (1.2 eq, 5.8 ml, 41.62 
mmols) were mixed in anhydrous dichloromethane (40 ml) on ice-bath. 3-
Chloropropionyl-chloride (1.05 eq, 3.47 ml, 36.41 mmols) was added dropwise keeping 
the temperature below 10 
o
C. The reaction was stirred for 1 hour. Saturated NaHCO3 (25 
ml) was added and the aqueous layer was extracted by dichloromethane (3 * 10ml). The 
organic layer was dried by anhydrous MgSO4, filtered and dried. The crude was purified 
by combi-flash chromatography using silica column and EtOAC:MeOH as  eluents to 
give a yellow solid (2.49 g, 50 %). 
1
H NMR (400 MHz, Chloroform-d) δ 1H NMR (400 
MHz, DMSO-d6) δ 10.66 (s, 1H), 8.81 (dd, J = 4.2, 1.7 Hz, 1H), 8.41 – 8.29 (m, 2H), 
8.00 (d, J = 9.0 Hz, 1H), 7.81 (dd, J = 9.1, 2.4 Hz, 1H), 7.50 (dd, J = 8.3, 4.2 Hz, 1H), 
3.93 (t, J = 6.3 Hz, 2H), 2.90 (t, J = 6.3 Hz, 2H). 
PL326 (N-(3-chloropropyl)quinolin-6-amine) 
PL323 (1 eq, 1.87 g, 7.97 mmol) was dissolved in tetrahydrofuran (20ml). LiAlH4 in 1M 
THF (3eq, 23.9ml, 23.9 mmol) was slowly added under N2 in an ice-bath. An additional 
30ml of THF was added and the reaction was allowed to stir overnight . After completion 
was confirmed by TLC, the reaction mixture was quenched with EtOAc (20ml) and 
MeOH (20ml), and then by citric acid solution. After filtering the yellow precipitate, the 
solution was extracted using diethyl-ether (2 * 20ml). The organic layer was separated, 
dried by anhydrous MgSO4, filtered and concentrated to get a brownish-oily compound 
(1.01g, 57.4%). 
1
H NMR (400 MHz, Chloroform-d) δ 8.61 – 8.53 (m, 1H), 7.94 – 7.87 
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(m, 1H), 7.84 (d, J = 9.1 Hz, 1H), 7.23 (dt, J = 8.3, 4.2 Hz, 1H), 7.06 (dd, J = 9.1, 2.6 Hz, 
1H), 6.66 (dd, J = 8.0, 2.6 Hz, 1H), 3.17 (t, J = 7.2 Hz, 2H), 1.72 – 1.66 (m, 2H), 1.04 (t, 
J = 7.4 Hz, 2H).  
PL334 (2-chloro-N-(quinolin-6-yl)acetamide) 
6-aminoquinoline (1 eq, 1.0 g, 6.94 mmol) and triethylamine (1.2 eq, 1.16 ml, 14.15 
mmols) were mixed in anhydrous dichloromethane (40 ml) on ice-bath. Chloro-
acetylchloride (1.05 eq, 0.58 ml, 7.29 mmols) was added dropwise keeping the 
temperature below 10
o
C. The reaction was stirred for 1 hour. Saturated NaHCO3 (25 ml) 
was added and the aqueous layer was extracted by DCM (3 * 10ml). The organic layer 
was dried by anhydrous MgSO4, filtered and dried. The crude was purified by combi-
flash chromatography using silica column and EtOAC:MeOH as  eluents to give a pure 
solid (1.10 g, 66 %). 
1
H NMR (400 MHz, Chloroform-d) δ 8.87 (dd, J = 4.2, 1.7 Hz, 1H), 
8.53 (s, 1H), 8.35 (d, J = 2.4 Hz, 1H), 8.18 – 8.13 (m, 1H), 8.10 (d, J = 9.0 Hz, 1H), 7.65 
(dd, J = 9.0, 2.5 Hz, 1H), 7.42 (dd, J = 8.3, 4.2 Hz, 1H), 4.26 (s, 2H).  
PL369 (3-(4-benzhydrylpiperazin-1-yl)-N-(quinolin-6-yl)propanamide) 
PL323 (1eq, 2.0g, 8.53 mmol) was dissolved in acetonitrile (40 ml). 1-
benzhydrylpiperazine (1.05 eq, 2.26 g, 8.96 mmol), anhydrous K2CO3 (2.4 eq, 2.97 g, 
21.50 mmol) and KI (1 eq, 1.42 g, 8.53 mmol) were all added to the solution. The 
reaction was refluxed with stirring for 3 days. After completion was confirmed, the 
acetonitrile solvent was evaporated and the slurry was taken up by EtOAC (20 ml) and 
water (40 ml). The aqueous phase was extracted by EtOAC (2 * 10 ml) and the organic 
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layer was washed with saturated NaHCO3 (15 ml), and then washed with brine (20 ml). 
The organic layer was dried by anhydrous MgSO4, filtered and concentrated. The crude 
was purified by combi-flash chromatography using silica column and and EtOAC:MeOH 
(85:15) as eluents to give a yellowish solid (1.6 g, 80 %). 
1
H NMR (400 MHz, 
Chloroform-d) δ 11.41 (s, 1H), 8.81 (dd, J = 4.3, 1.7 Hz, 1H), 8.44 (d, J = 2.3 Hz, 1H), 
8.14 – 8.09 (m, 1H), 8.02 (d, J = 9.0 Hz, 1H), 7.48 – 7.43 (m, 4H), 7.41 – 7.34 (m, 2H), 
7.31 (dd, J = 8.3, 6.8 Hz, 4H), 7.25 – 7.19 (m, 2H), 4.38 (s, 1H), 2.50–2.81 (ddd, J = 80.7, 
7.0, 5.2 Hz, 8H). 
13
C NMR (101 MHz, Chloroform-d) δ 171.0, 149.1, 145.3, 142.1, 
136.6, 135.9, 130.1, 128.6, 128.0, 127.2, 123.1, 121.5, 115.6, 75.9, 53.6, 52.6, 52.0, 32.5. 
m/z 450.25 M + H (calculated 450.59). 
PL370 (N-(3-(4-benzhydrylpiperazin-1-yl)propyl)quinolin-6-amine) 
PL369 (1 eq, 1.6 g, 3.66 mmol) was dissolved in tetrahydrofuran (20 ml). Under N2, 
LiAlH4 in 2.5M THF (5 eq, 7.33 ml, 18.31 mmol) was added into the reaction mixture. 
The reaction was allowed to run at 0 
o
C overnight. After completion, the solution was 
quenched by citric acid solution. To the yellow-greenish suspension formed, NaOH (2.75 
M, 1 ml) and saturated NaHCO3 (20 ml) was added, and the aqueous phase was extracted 
with diethylether (2 * 15 ml). The organic phase was washed with water (10 ml) and 
salted out with brine (10 ml). Finally, the organic layer was dried by anhydrous MgSO4, 
filtered and evaporated to give a brownish, oily solid. The crude (0.76 g) was purified by 
combi-flash chromatography by dissolving in acetone and small amount of methanol. 
Silica gel sorbent (7.6 g) was added and the suspension was stirred on sonicator before 
evaporating the solvent. The solid was purified in silica column (40 g) using 
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EtOAC:MeOH (85:15) as eluents by collecting only the peaks for 20 minutes twice (0.42 
g, 56 %). 
1
H NMR (400 MHz, Chloroform-d) δ 8.58 (dd, J = 4.3, 1.7 Hz, 1H), 7.91 – 
7.81 (m, 2H), 7.47 – 7.39 (m, 4H), 7.32 – 7.15 (m, 8H), 7.02 (dd, J = 9.1, 2.6 Hz, 1H), 
6.62 (d, J = 2.6 Hz, 1H), 4.28 (s, 1H), 3.26 (t, J = 6.2 Hz, 2H), 2.61 – 2.34 (m, 10H), 1.84 
(p, J = 6.3 Hz, 2H). 
13
C NMR (101 MHz, Chloroform-d) δ 149.1, 145.3, 142.1, 136.6, 
135.9, 130.1, 128.6, 128.0, 127.2, 123.1, 121.5, 115.6, 75.9, 53.6, 52.6, 52.0, 41.1, 32.5. 
m/z 436.27 M + H (calculated 436.60). 
PL403 (7-chloro-N-(3-(4-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-1-
yl)propyl)quinolin-4-amine) 
To a stirred solution of PL409 (1 eq, 0.16 g, 0.61 mmol), 4-
(trifluoromethoxy)phenylacetylene (1.07 eq, 0.1 ml,  0.65 mmol) in tert-butanol (7 ml),  
was added a solution of CuSO4. 5H2O (0.2 eq, 0.030 g, 0.12 mmol) and sodium ascorbate 
(0.4 eq, 0.048 g, 0.24 mmol) in water (7 ml), and the mixture was stirred for 4 hours at 40 
o
C. After completion, CHCl3 (20 ml) was added and the mixture was washed with water 
(2 * 100 ml). Finally the organic layer was dried by anhydrous MgSO4, filtered and 
concentrated to give a white solid (0.08 g, 30 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.68 
(s, 1H), 8.41 (s, 1H), 8.26 (d, J = 9.0 Hz, 1H), 7.99 – 7.90 (m, 2H), 7.79 (s, 1H), 7.50 – 
7.41 (m, 3H), 7.36 (t, J = 5.4 Hz, 1H), 6.49 (d, J = 4.9 Hz, 1H), 4.58 (t, J = 6.9 Hz, 2H), 
3.37 (d, J = 6.5 Hz, 2H), 2.30 (p, J = 6.9 Hz, 2H), 13C NMR (101 MHz, DMSO-d6) δ 
145.0, 133.4, 130.2 ,126.9 , 124.1, 122.0, 121.6, 47.7, 40.1, 28.3. m/z 447.11 M + H 
(calculated 447.85). 
 
 80 
 
PL404 ((1-(3-((7-chloroquinolin-4-yl)amino)propyl)-1H-1,2,3-triazol-4-
yl)diphenylmethanol) 
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 1,1-diphenyl-2-propyn-1-ol (1.07 
eq, 0.42 g,  2.84 mmol) in tert-butanol (23 ml),  a solution of CuSO4. 5H2O (0.2 eq, 0.095 
g, 0.38 mmol) and sodium ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (23 ml) was 
added, and the mixture was stirred for 3 hours at 40 
o
C. After completion, the reaction 
mixture was cooled to RT and taken by CHCl3 (60 ml) and washed with water (3 * 300 
ml). Finally the organic layer was dried by anhydrous MgSO4, filtered and concentrated  
The crude was purified using combi-flash chromatography in silica column by eluting 
using CHCl3:MeOH (90:10) to give a pure white-yellowish solid (0.35 g, 41 %). 
1
H 
NMR (400 MHz, DMSO-d6) δ 8.37 (d, J = 5.4 Hz, 1H), 8.26 (d, J = 9.0 Hz, 1H), 7.88 (s, 
1H), 7.79 (d, J = 2.3 Hz, 1H), 7.46 (dd, J = 9.0, 2.3 Hz, 1H), 7.40 – 7.17 (m, 10H), 6.54 
(s, 1H), 6.40 (d, J = 5.4 Hz, 1H), 4.51 (t, J = 6.9 Hz, 2H), 3.33 – 3.24 (m, 2H), 2.22 (p, J 
= 7.0 Hz, 2H). 
13
C NMR (101 MHz, DMSO-d6) δ 153.9 , 151.9 , 149.9 , 149.0 , 147.1 , 
133.4 , 127.5 (d, J = 3.6 Hz), 127.0 , 126.6 , 124.1 (d, J = 3.8 Hz), 123.4 , 117.5 , 98.6 , 
75.7 , 59.7 , 47.2 , 38.9 , 28.5 , 14.1. m/z 469.17 M + H (calculated 469.97). 
PL405 (7-chloro-N-(3-(4-(2-methoxyphenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-
amine) 
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 2-ethynylanisole (1.07 eq, 0.26 
ml,  2.04 mmol) in tert-butanol (19 ml),  was added CuSO4. 5H2O (0.2 eq, 0.095 g, 0.38 
mmol) and sodium ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (19 ml),  and the 
mixture was stirred for 3 hours at 40 
o
C. After completion, the crude mixture was taken 
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by CHCl3 (25 ml) and washed with water (3 * 120 ml). Finally the organic layer was 
dried by anhydrous MgSO4, filtered and concentrated. The crude was purified using 
combi-flash chromatography in silica column by eluting using CHCl3:MeOH (90:10) to 
give a pure solid (0.54 g, 72 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 1H), 8.34 – 
8.26 (m, 1H), 8.13 (dd, J = 7.7, 1.8 Hz, 1H), 7.81 (s, 1H), 7.45 (dd, J = 13.8, 7.3 Hz, 2H), 
7.33 (td, J = 8.0, 1.8 Hz, 1H), 7.16 – 6.99 (m, 3H), 6.51 (s, 1H), 4.58 (t, J = 6.9 Hz, 2H), 
3.89 (s, 3H), 3.34 (q, J = 6.4 Hz, 2H), 2.29 (p, J = 6.7 Hz, 2H). 
13
C NMR (101 MHz, 
DMSO-d6) δ 155.3 , 141.7 , 133.5 , 128.8 , 126.5 , 124.2 , 124.0 , 120.6 , 119.1 , 111.5 , 
55.4 , 47.4 , 40.1 , 28.5. m/z 393.14 M + H (calculated 393.88). 
PL406 (7-chloro-N-(3-(4-(3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-
amine) 
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 3-ethynylanisole (1.07 eq, 0.26 
ml,  2.04 mmol) in tert-butanol (19 ml),  was added CuSO4. 5H2O (0.2 eq, 0.095 g, 0.38 
mmol) and sodium ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (19 ml) was added and 
the mixture was stirred for 3 hours at 40 
o
C. After completion, the crude mixture was 
taken by CHCl3 (25 ml) and washed with water (3 * 120 ml). Finally the organic layer 
was dried by anhydrous MgSO4, filtered and concentrated. The crude was purified using 
combi-flash chromatography in silica column by eluting using CHCl3:MeOH (90:10) to 
give a pure white-yellowish solid (0.38 g, 51 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.64 
(s, 1H), 8.29 (d, J = 8.9 Hz, 1H), 7.81 (s, 1H), 7.54 – 7.31 (m, 5H), 6.90 (ddd, J = 8.1, 
2.6, 1.2 Hz, 1H), 6.53 (s, 1H), 4.56 (t, J = 6.9 Hz, 2H), 3.81 (s, 3H), 3.36 (q, J = 6.5 Hz, 
2H), 2.30 (p, J = 7.0 Hz, 2H). 
13
C NMR (101 MHz, DMSO-d6) δ 159.6 , 150.2 , 146.2 , 
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133.7 , 132.1 , 130.0 , 124.2, 121.7 , 117.4 , 113.5 , 110.3 , 55.1 , 47.6 , 38.9 , 28.3. m/z 
393.14 M + H (calculated 393.88). 
PL407 (7-chloro-N-(3-(4-(2-fluorophenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-
amine) 
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 2-fluorophenylacetlene (1.07 eq, 
0.24 ml,  2.04 mmol) in tert-butanol (15 ml),  was added CuSO4. 5H2O (0.2 eq, 0.095 g, 
0.38 mmol) and sodium ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (15 ml) was added 
and the mixture was stirred for 3 hours at 40 
o
C. After completion, the mixture of 
solvents was evaporated and the solid was purified using combi-flash chromatography in 
silica column by eluting using CHCl3:MeOH (90:10) to give a pure white-yellowish solid 
(0.10 g, 26 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.50 (d, J = 3.7 Hz, 1H), 8.41 (d, J = 
5.3 Hz, 1H), 8.26 (dd, J = 9.0, 5.6 Hz, 1H), 8.13 (td, J = 7.6, 1.7 Hz, 1H), 7.79 (d, J = 2.4 
Hz, 1H), 7.45 (dd, 1H), 7.40 (dt, 1H), 7.34(t, 3H), 6.48 (dd, J = 11.0, 5.4 Hz, 1H), 4.62 (t, 
J = 6.7 Hz, 2H), 3.32 (s, 2H), 2.30 (p, J = 6.8 Hz, 2H).
13
C NMR (101 MHz, DMSO-d6) δ 
151.9, 149.9, 149.0 , 133.4 , 127.4, 124.9 , 124.1 , 117.5 , 98.7 , 48.5 , 47.6 , 40.1 , 28.4 , 
27.1. m/z 381.12 M + H (calculated 381.84). 
PL408 (7-chloro-N-(3-(4-(3,4-difluorophenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-
4-amine) 
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 3,4-difluorophenylacetlene (1.07 
eq, 0.25 ml,  2.04 mmol) in tert-butanol (15 ml), CuSO4. 5H2O (0.2 eq, 0.095 g, 0.38 
mmol) and sodium ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (15 ml) was added and 
the mixture was stirred for 3 hours at 40 
o
C. After completion, the mixture of solvents 
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was evaporated and the solid was purified using combi-flash chromatography in silica 
column by eluting using CHCl3:MeOH (90:10) to give a pure white-yellowish solid (0.58 
g, 76 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.66 (s, 1H), 8.40 (d, 1H), 8.24 (d, 1H), 7.84 
(dt, 1H), 7,78 (d, 1H), 7.67 (dtd, J = 10.6, 4.6, 3.6, 1.9 Hz, 1H), 7.60 – 7.29 (m, 3H), 6.49 
(d, 1H), 4.56 (t, 2H), 3.36 (dd, J = 14.3, 7.7 Hz, 2H), 2.29 (p, J = 7.2 Hz, 2H). 
13
C NMR 
(101 MHz, DMSO-d6) δ 151.9 , 149.9, 148.9, 133.4, 127.5 , 124.1, 122.1 , 118.2 , 98.8 , 
47.7 , 40.1 , 28.2. m/z 399.11 M + H (calculated 399.83). 
PL409 (N-(3-azidopropyl)-7-chloroquinolin-4-amine) 
PL29 (1 eq, 7.0 g, 22.2 mmol) was dissolved in anhydrous dimethylformamide (100ml). 
Sodium azide (2 eq, 2.9 g, 44.5 mmol) was added and the mixture was stirred at 55 
o
C for 
12 hours. After completion, De-ionized water (135 ml) was added and the aqueous layer 
was extracted with toluene (3*330ml). The organic layer was dried with brine (130ml), 
dried by anhydrous MgSO4, filtered and evaporated to give yellow solid (5.1 g, 88 %). 
1
H 
NMR (400 MHz, Chloroform-d) δ 8.55 (d, J = 5.3 Hz, 1H), 7.96 (d, J = 2.1 Hz, 1H), 7.67 
(d, J = 8.9 Hz, 1H), 7.36 (dd, J = 9.0, 2.2 Hz, 1H), 6.42 (d, J = 5.3 Hz, 1H), 5.35 (t, J = 
5.4 Hz, 1H), 3.57 – 3.40 (m, 4H), 2.02 (p, J = 6.6 Hz, 2H).  
PL410 (N
1
-(7-chloroquinolin-4-yl)-N3-methyl-N3-(3-phenyl-3-(4-
(trifluoromethyl)phenoxy)propyl)propane-1,3-diamine)  
First, the free base fluoxetine was prepared by dissolving fluoxetine HCl (1 eq, 0.55 g, 
1.59 mmol) in water (7ml). Solid NaHCO3 (2.28 eq, 0.30 g, 3.62 mmol) was added and 
the mixture was extracted with dichloromethane (9ml * 3). The organic phase was dried 
with anhydrous MgSO4, filtered and evaporated to give yellow oliy liquid (0.51g, 93%). 
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The free-base fluoxetine (1 eq, 0.51 g, 1.65 mmol) was dissolved in tetrahydrofuran 
(18ml), followed by addition of PL29 (1.33 eq, 0.69 g, 2.19 mmol) and triethylamine (2.9 
eq, 0.67 ml, 4.79 mmol) and the reaction mixture was stirred for 72 hours at 55 
o
C. After 
the reaction completion was confirmed by TLC on alumina plate, the reaction was cooled 
to RT and THF was evaporated by rotovap. The crude was washed with EtOAC (25ml) 
and saturated NaHCO3 (25ml). The organic layer was separated and the aqueous layer 
was washed with EtOAC (2*15ml). The organic layer was finally dried by anhydrous 
MgSO4, filtered and evaporated. The crude was purified by combi-flash chromatography 
on alumina column using EtOAC:Hexane as eluents to get a yellow solid (0.6g, 69%). 
1
H 
NMR (400 MHz, DMSO-d6) δ 8.37 (d, J = 5.4 Hz, 1H), 8.21 (d, J = 9.0 Hz, 1H), 7.78 (d, 
J = 2.2 Hz, 1H), 7.56 – 7.38 (m, 3H), 7.37 – 7.19 (m, 6H), 6.98 (d, J = 8.6 Hz, 2H), 6.40 
(d, J = 5.5 Hz, 1H), 5.44 (dd, J = 8.2, 4.8 Hz, 1H), 3.49 – 3.37 (m, 2H), 3.23 (dtd, J = 
19.6, 12.8, 6.4 Hz, 2H), 2.57 – 2.26 (m, 2H), 2.19 (s, 3H), 2.16 – 1.86 (m, 2H), 1.86 – 
1.70 (m, 2H). 
13
C NMR (101 MHz, DMSO-d6) δ 160.5, 151.9, 150.1, 149.0, 141.0, 
133.3, 128.5, 127.6, 126.9 – 126.6 (m), 125.9 , 124.0 (d, J = 4.8 Hz), 120.8 , 117.4 , 
116.0 , 98.6 , 77.4 , 54.8 , 53.2 , 41.9 , 40.7 , 35.7 , 25.3 , 22.3. m/z 527.20 M + H 
(calculated 528.02). 
PL411 (7-chloro-N-(3-(4-phenyl-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-amine) 
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), Ethynyl-benzene (1eq, 0.21ml, 
1.9mmol) in tert-butanol (5ml), CuSO4. 5H2O (0.2eq, 0.095g, 0.38mmol) and sodium 
ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (5ml) was added and the mixture was 
stirred for 4 hours at 40 
o
C. After completion, the mixture of solvents was evaporated and 
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the solid was purified using combi-flash chromatography in silica column by eluting 
using CHCl3:MeOH (90:10) to give a pure white-yellowish solid (0.34g, 50%). 
1
H NMR 
(400 MHz, DMSO-d6) δ 8.62 (s, 1H), 8.40 (d, J = 5.4 Hz, 1H), 8.27 (d, 1H), 7.94 – 7.74 
(m, 3H), 7.50 – 7.28 (m, 5H), 6.48 (dd, J = 5.5, 3.7 Hz, 1H), 4.59 (dt, J = 11.1, 6.9 Hz, 
2H), 3.34 (dt, J = 13.4, 6.9 Hz, 2H), 2.30 (q, 2H). 
13
C NMR (101 MHz, DMSO-d6) δ 
151.9, 149.9 (d, J = 5.9 Hz), 149.5, 148.9, 146.3, 137.1, 133.4, 130.8, 128.9, 127.8, 
127.5, 125.1, 124.1 (d, J = 3.6 Hz), 122.9, 121.5, 119.3, 117.5, 98.7, 47.6, 40.1, 28.34. 
m/z 363.13 M + H (calculated 363.85). 
PL412 (7-chloro-N-(3-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-
amine) 
To a stirred solution of PL409 (1 eq, 0.25 g, 1.9 mmol), 2-Ethynylpyridine (1eq, 0.1ml, 
1.9 mmol) in tert-butanol (5ml), CuSO4. 5H2O (0.2eq, 0.095g, 0.38mmol) and sodium 
ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (5ml) was added and the mixture was 
stirred for 4 hours at 40 
o
C. After completion, the mixture of solvents was evaporated and 
the solid was purified using combi-flash chromatography in silica column by eluting 
using CHCl3:MeOH (90:10) to give a yellow solid (0.16g, 46%). 
1
H NMR (400 MHz, 
DMSO-d6) δ 8.48 (s, 2H), 7.45 (s, 1H), 7.37 (s, 1H), 6.76 (s, 1H), 4.70 (s, 2H), 3.17 (d, J 
= 5.0 Hz, 2H), 2.09 (s, 2H). 
PL413 (7-chloro-N-(3-(4-(p-tolyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-amine) 
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 4-Ethynyltoluene (1 eq, 0.24 ml, 
1.9 mmol) in tert-butanol (5ml), CuSO4. 5H2O (0.2eq, 0.095g, 0.38mmol) and sodium 
ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (5ml) was added and the mixture was 
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stirred for 4 hours at 40 
o
C. After completion, the mixture of solvents was evaporated and 
the solid was recrystallized by CHCl3:MeOH (90:10) to give a pure solid (0.4g, 56%). 
1
H 
NMR (400 MHz, DMSO-d6) δ 8.55 (s, 1H), 8.41 (s, 1H), 8.29 (d, 1H), 7.81 (d, 1H), 7.71 
(d, 2H), 7.46 (d, 1H), 7.43 (t, 1H), 7.25 (d, 2H), 6.52 (d, 1H), 4.55 (t, 2H), 3.43 (d, 2H), 
2.32 (s, 3H), 2.27 (q, 2H). 
13
C NMR (101 MHz, DMSO-d6) δ 137.1, 129.4, 128.0, 125.0, 
121.1, 47.5, 28.1, 20.8. m/z 377.14 M + H (calculated 377.88). 
PL414 (N-(3-(4-benzyl-1H-1,2,3-triazol-1-yl)propyl)-7-chloroquinolin-4-amine) 
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 3-phenyl-1-propyne (1 eq, 0.24 
ml, 1.9 mmol) in tert-butanol (5ml), CuSO4. 5H2O (0.2eq, 0.095g, 0.38mmol) and 
sodium ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (5ml) was added and the mixture 
was stirred for 4 hours at 40 
o
C. After completion, the mixture of solvents was evaporated 
and the solid was recrystallized by CHCl3:MeOH (90:10) to give a pure solid (0.33 g, 
45%). 
1
H NMR (400 MHz, DMSO-d6) δ 8.31 (d, J = 6.1 Hz, 1H), 7.88 (s, 1H), 7.82 (d, 
1H), 7.46 (dd, J = 10.5, 7.1 Hz, 2H), 7.35 – 7.15 (m, 6H), 6.48 (s, 1H), 4.46 (t, J = 6.9 Hz, 
2H), 3.98 (s, 2H), 3.28 (q, J = 6.5 Hz, 2H), 2.20 (p, J = 6.9 Hz, 2H). 
13
C NMR (101 MHz, 
DMSO-d6) δ 150.1, 146.1, 139.6, 133.6, 128.4(d, J = 8.9 Hz), 126.1, 124.3, 122.6, 47.2, 
38.9, 31.3, 28.4. m/z 377.14 M + H (calculated 377.88). 
PL415 (N-(3-(4-(4-aminophenyl)-1H-1,2,3-triazol-1-yl)propyl)-7-chloroquinolin-4-
amine) 
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 4-ethynylaniline (1 eq, 0.22 g, 
1.9 mmol) in tert-butanol (5 ml), CuSO4. 5H2O (0.2 eq, 0.095 g, 0.38 mmol) and sodium 
ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (5ml) was added and the mixture was 
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stirred for 4 hours at 40 
o
C. After completion, the mixture of solvents was evaporated and 
the solid was recrystallized by CHCl3 : MeOH (90:10) to give a pure solid (0.52 g, 72 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.40 (s, 1H), 8.28 (d, J = 20.1 Hz, 2H), 7.80 (d, J = 2.4 
Hz, 1H), 7.53 – 7.35 (m, 4H), 6.62 (m, 2H), 6.48 (d, J = 5.4 Hz, 1H), 5.22 (s, 2H), 4.51 (t, 
J = 6.9 Hz, 2H), 3.35 (m, 2H), 2.25 (dq, J = 11.5, 5.8, 4.6 Hz, 2H). 
13
C NMR (101 MHz, 
DMSO-d6) δ 151.8, 150.0, 148.5, 147.3, 133.5, 127.3, 126.1, 124.1 (d, J = 8.6 Hz), 
119.3, 118.4, 113.9, 98.8, 47.3, 38.8, 28.4. m/z 378.14 M + H (calculated 378.86). 
PL416 (N-(3-(4-(4-bromophenyl)-1H-1,2,3-triazol-1-yl)propyl)-7-chloroquinolin-4-
amine) 
To a stirred solution of PL409 (1 eq, 0.25 g, 0.95 mmol), 1-Bromo-4-Ethynylbenzene (1 
eq, 0.17 g, 0.95 mmol) in tert-butanol (4 ml), CuSO4. 5H2O (0.2 eq, 0.047 g, 0.19 mmol) 
and sodium ascorbate (0.4eq, 0.075 g, 0.38 mmol) in water (4 ml) was added and the 
mixture was stirred for 4 hours at 40 
o
C. After completion, the mixture of solvents was 
evaporated and the solid was recrystallized by CHCl3 : MeOH (90:10) to give a pure solid 
(0.29 g, 69 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.65 (s, 1H), 8.58 (s, 1H), 7.78 (d, J = 
8.1 Hz, 2H), 7.68 – 7.55 (m, 3H), 7.45 (d, J = 8.6 Hz, 1H), 4.56 (t, J = 6.8 Hz, 2H), 3.34 
(d, J = 5.9 Hz, 2H), 2.35 – 2.19 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 145.3, 131.8, 
129.9, 127.1, 124.6, 121.9, 120.8, 47.6, 40.1, 38.8, 28.1. m/z 443.04 M + H (calculated 
442.75). 
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PL417 (7-chloro-N-(3-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-
amine) 
To a stirred solution of PL409 (1 eq, 0.25 g, 0.95 mmol),  4-Ethynylanisole (1 eq, 0.13 
ml, 0.95 mmol) in tert-butanol (4 ml), CuSO4. 5H2O (0.2 eq, 0.047 g, 0.19 mmol) and 
sodium ascorbate (0.4eq, 0.075 g, 0.38 mmol) in water (4 ml) was added and the mixture 
was stirred for 4 hours at 40 
o
C. After completion, the mixture of solvents was evaporated 
and the solid was recrystallized by CHCl3 : MeOH (90:10) to give a pure solid (0.19 g, 
51 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.49 (s, 1H), 8.33 (s, 1H), 7.84 (s, 1H), 7.79 – 
7.70 (m, 2H), 7.54 – 7.43 (m, 2H), 7.05 – 6.97 (m, 2H), 6.57 (s, 1H), 4.54 (t, J = 6.9 Hz, 
2H), 3.79 (d, J = 1.2 Hz, 3H), 3.34 (d, J = 6.4 Hz, 2H), 2.27 (tt, J = 12.9, 5.7 Hz, 2H). 
13
C 
NMR (101 MHz, DMSO-d6) δ 158.9, 146.2, 126.4, 124.3, 120.5, 114.3, 55.1, 47.5, 38.8, 
28.3. m/z 393.14 M + H (calculated 393.88). 
PL418 (7-chloro-N-(3-(4-(4-chlorophenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-
amine) 
To a stirred solution of PL409 (1 eq, 0.25 g, 0.95 mmol), 1-Chloro-4-Ethynylbenzene (1 
eq, 0.13 g, 0.95 mmol) in tert-butanol (4 ml), CuSO4. 5H2O (0.2 eq, 0.047 g, 0.19 mmol) 
and sodium ascorbate (0.4eq, 0.075 g, 0.38 mmol) in water (4 ml) was added and the 
mixture was stirred for 4 hours at 40 
o
C. After completion, the mixture of solvents was 
evaporated and the solid was recrystallized by CHCl3 : MeOH (90:10) to give a pure solid 
(0.28 g, 76 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.64 (s, 1H), 7.84 (d, J = 8.3 Hz, 2H), 
7.48 (dd, J = 26.9, 8.3 Hz, 4H), 6.91 (s, 1H), 4.57 (t, J = 6.7 Hz, 2H), 3.34 (p, J = 5.4, 4.4 
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Hz, 2H), 2.36 – 2.19 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 145.2, 132.2, 129.6, 
128.9, 126.8, 124.5, 121.8, 47.6, 38.8, 28.9, 28.1. m/z 397.09 M + H (calculated 398.29). 
PL419 (7-chloro-N-(3-(4-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-
yl)propyl)quinolin-4-amine) 
To a stirred solution of PL409 (1 eq, 0.25 g, 0.95 mmol), 1-Ethynyl-4-(trifluoromethyl) 
benzene) (1 eq, 0.16 ml, 0.95 mmol) in tert-butanol (4 ml), CuSO4. 5H2O (0.2 eq, 0.047 
g, 0.19 mmol) and sodium ascorbate (0.4eq, 0.075 g, 0.38 mmol) in water (4 ml) was 
added and the mixture was stirred for 4 hours at 40 
o
C. After completion, the mixture of 
solvents was evaporated and the solid was recrystallized by CHCl3 : MeOH (90:10) to 
give a pure solid (0.28 g, 68 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.34 (s, 
1H), 8.04 (d, J = 8.0 Hz, 2H), 7.81 (d, J = 8.0 Hz, 2H), 7.58 (t, J = 5.3 Hz, 1H), 7.46 (d, J 
= 8.8 Hz, 1H), 6.63 (s, 1H), 4.60 (t, J = 6.7 Hz, 2H), 3.39 (q, J = 6.0 Hz, 2H), 2.32 (p, J = 
6.9 Hz, 2H). 
13
C NMR (101 MHz, DMSO-d6) δ 144.9, 134.7, 133.8, 127.8, 125.9 – 125.7 
(m), 125.6, 124.4, 122.8 (d, J = 9.9 Hz), 47.7, 38.8, 28.1. m/z 431.12 M + H (calculated 
431.85). 
PL420 (7-chloro-N-(3-(4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-
amine) 
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 1-Ethynyl-4-Fluorobenzene (1 
eq, 0.23 g, 1.9 mmol) in tert-butanol (5 ml), CuSO4. 5H2O (0.2 eq, 0.095 g, 0.38 mmol) 
and sodium ascorbate (0.4eq, 0.15 g, 0.76 mmol) in water (5 ml) was added and the 
mixture was stirred for 4 hours at 50 
o
C. After completion, the mixture of solvents was 
evaporated and the solid was recrystallized by CHCl3 : MeOH (90:10) to give a pure solid 
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(0.61 g, 84 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.45 (s, 1H), 7.92 – 7.81 
(m, 2H), 7.45 (d, J = 8.4 Hz, 2H), 7.29 (t, J = 8.8 Hz, 2H), 6.72 (s, 1H), 4.57 (t, J = 6.8 
Hz, 2H), 3.44 – 3.29 (m, 2H), 2.36 – 2.19 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 
145.5, 133.4, 127.4 – 126.9 (m), 124.3, 121.4, 115.9, 115.7, 47.6, 38.8, 28.2. m/z 381.12 
M + H (calculated 381.84). 
PL421 (7-chloro-N-(3-(4-(4-nitrophenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-
amine) 
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 1-Ethymyl-4-Nitrobenzene (1 eq, 
0.28 g, 1.9 mmol) in tert-butanol (5 ml), CuSO4. 5H2O (0.2 eq, 0.095 g, 0.38 mmol) and 
sodium ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (5 ml) was added and the mixture 
was stirred for 4 hours at 40 
o
C. After completion, the mixture of solvents was evaporated 
and the solid was recrystallized by CHCl3 : MeOH (90:10) to give a pure solid (0.74 g, 
95 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.85 (s, 1H), 8.36 – 8.25 (m, 3H), 8.12 – 8.04 
(m, 2H), 7.82 (s, 1H), 7.43 (dd, J = 9.9, 5.6 Hz, 2H), 6.56 (s, 1H), 4.61 (t, J = 6.9 Hz, 
2H), 3.37 (q, J = 6.1 Hz, 2H), 2.37 – 2.12 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 
144.4, 125.8, 124.3 (d, J = 11.4 Hz), 123.6, 47.9, 38.8, 28.9, 28.1. m/z 408.11 M + H 
(calculated 408.85). 
PL422 (N-benzhydrylprop-2-yn-1-amine) 
A solution of benzhydramine (1.4 eq, 3 ml, 17 mmol) in anhydrous ether (40ml) was 
treated with propargyl bromide in 80% toluene (1 eq, 1.35 ml, 12.2 eq), and catalytic 
amount of NaI. The reaction was heated with stirring at 35 
o
C for 16 hours. After 
completion, the reaction mixture was washed with water (2*20ml) and the organic layer 
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was dried by anhydrous MgSO4, filtered and concentrated. The crude was purified using 
combi-flash chromatography in silica column by eluting in Hexanes:EtOAC (95:5) 
mixture to giving a pure yellow solid (1.1 g, 42 %). 
1
H NMR (400 MHz, Chloroform-d) δ 
7.45 – 7.40 (m, 4H), 7.32 – 7.27 (m, 4H), 7.25 – 7.18 (m, 2H), 5.10 (s, 1H), 3.36 (d, J = 
2.5 Hz, 2H), 2.25 (t, J = 2.4 Hz, 1H), 1.82 – 1.67 (m, 1H). 
PL423 (N-(3-(4-((benzhydrylamino)methyl)-1H-1,2,3-triazol-1-yl)propyl)-7-
chloroquinolin-4-amine) 
To a stirred solution of PL409 (1 eq, 0.55 g, 2.11 mmol), PL422 (1.07 eq, 0.50 g, 2.26 
mmol) in tert-butanol (10 ml), a solution of CuSO4. 5.H2O (0.2 eq, 0.10 g, 0.42 mmol) 
and sodium ascorbate (0.4 eq, 0.17 g, 0.84 mmol) in water (10ml) was added. The 
mixture was stirred for 4 hours at 40 
o
C. After completion was confirmed by TLC, 
chloroform (25 ml) was added and the organic layer was washed by DI-water (3*125 ml), 
and then with brine (50 ml). Finally, the organic layer was dried by anhydrous MgSO4 , 
filtered and concentrated. The crude was purified in combi-flash using silica column and 
CHCl3 : MeOH (95:5) as eluents obtaining pure solid (0.47 g, 46 %). 
1
H NMR (400 MHz, 
DMSO-d6) δ 8.40 (s, 1H), 8.28 (d, J = 9.1 Hz, 1H), 8.02 (s, 1H), 7.80 (d, 1H), 7.46 (dd, J 
= 9.1 Hz, 1H), 7.40 (t, 4H), 7.35 (t, 1H), 7.28 (dt, 4H), 7.18 (t, 2H), 6.45 (d, J = 5.3 Hz, 
1H), 5.10 (s, 1H), 4.83 (s, 1H), 4.50 (t, J = 6.9 Hz, 2H), 3.66 (s, 2H), 3.29 (q, J = 6.5 Hz, 
2H), 2.23 (p, J = 6.9 Hz, 2H). 
13C NMR (101 MHz, DMSO) δ 152.3, 124.6, 124.1, 123.3, 
127.9, 128.5, 124.6, 127.4, 128.7, 127.5, 129.4, 128.6, 127.1, 127.6, 99.2, 65.9, 59.7, 
47.7, 42.9, 40.0, 28.9. m/z 482.20 M + H (calculated 483.02). 
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PL424 (N-(piperidin-4-yl)-5H-cyclopenta[2,1-b:3,4-b']dipyridin-5-imine) 
To the protected amine (1 eq, 0.88 g, 2.62 mmol), solid NaOH (10 eq, 1.05 g, 26.2 mmol) 
in ethanol (20 eq, 3.1 ml, 52.3 mmol) was added and stirred at room temperature for 2 
hours. The solvent was evaporated, and the crude was taken by EtOAC (40 ml) and water 
(20 ml). The aqueous layer was extracted with CHCl3 (3 * 20 ml). The two organic layers 
were mixed and dried with anhydrous MgSO4, filtered and concentrated to give a 
brownish solid (0.37 g, 42 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.67 (ddd, J = 8.6, 4.9, 
1.5 Hz, 2H), 8.11 (dd, J = 8.0, 1.5 Hz, 1H), 7.95 (dd, J = 7.7, 1.6 Hz, 1H), 7.42 (ddd, J = 
20.5, 7.7, 4.9 Hz, 2H), 4.70 (tt, J = 9.1, 4.1 Hz, 1H), 3.97 (ddd, J = 16.4, 7.8, 4.1 Hz, 2H), 
3.86 (s, 2H), 2.85 (dq, J = 12.3, 3.7 Hz, 2H), 1.67 (m, 2H). 
PL425 (N-(3-(4-((5H-cyclopenta[2,1-b:3,4-b']dipyridin-5-ylidene)amino)piperidin-1-
yl)propyl)-7-chloroquinolin-4-amine) 
PL424 (1.5 eq, 1.1 g, 4.16 mmol) was dissolved in acetonitrile (15 ml), and PL29 (1 eq, 
0.87 g, 2.77 mmol) and K2CO3 (2 eq, 0.77 g, 5.44 mmol) were all added. The reaction 
mixture was refluxed at 70 
o
C while stirring for  3 days. After completion, the solvent 
was evaporated and the residue was slurred in water (30ml) and vaccum-filtered. The 
crude was recrystallized from Toluene:Hexane (50:50) mixture to recover a brownish 
solid (0.7 g, 52 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.75 (t, J = 5.7 Hz, 4H), 8.38 (dd, J 
= 27.1, 6.6 Hz, 4H), 8.27 (d, J = 9.0 Hz, 2H), 8.14 (d, J = 7.5 Hz, 2H), 7.79 (d, J = 2.4 
Hz, 2H), 7.56 – 7.40 (m, 10H), 7.30 – 7.08 (m, 8H), 6.52 (d, J = 5.4 Hz, 2H), 4.48 (tt, J = 
9.4, 4.7 Hz, 2H), 3.30 (s, 6H), 2.96 (dd, J = 9.7, 5.3 Hz, 3H), 2.49 (s, 1H), 2.29 (d, J = 6.1 
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Hz, 9H), 1.97 – 1.78 (m, 11H), 1.30 – 1.21 (m, 1H), 0.84 (dt, J = 10.8, 6.5 Hz, 1H). 13C 
NMR (101 MHz, DMSO-d6) δ 160.33 , 158.29 , 155.65 , 152.25 , 151.9, 151.7, 150.1, 
149.1, 134.9, 133.3, 132.9, 129.7, 128.9, 128.2, 127.5, 125.3, 124.6, 124.4, 123.9, 117.4, 
98.6, 55.9, 51.3, 40.9, 32.9, 25.2, 21.0. m/z 482.20 M + H (calculated 483.02). 
PL426 (7-chloro-N-(pyrrolidin-3-yl)quinolin-4-amine) 
4,7-dichloroquinoline (1 eq, 2.5 g, 12.5 mmol) was dissolved in N,N-
Diisopropylethylamine (50ml). 3-Aminopyrrolidine dihydrochloride (2 eq, 3.98 g, 25 
mmol) and CsCO3 (4 eq, 16.45 g, 50 mmol) was added slowly with stirring and the 
mixture was  refluxed for 4 hours. The solvent was evaporated and the crude was purified 
in combi-flash by DCM:MeOH:Et3N (8.9:1:0.1) as mixture of solvents to give orange-
colored solid (1.35 g, 44 %). 
1
H NMR (400 MHz, CDCl3): δ 8.69 (d, J = 4.8, 1H), 8.02 
(d, J = 2.0, 1H), 7.90 (d, J = 8.8, 1H), 7.42 (dd, J = 8.8, 2.0, 1H), 6.82 (d, J = 4.8, 1H), 
3.83 (m, 1H), 3.68 (m, 1H), 3.42 (m, 1H), 3.14 s, 1H), 2.14 (m, 1H), 1.85 (m, 1H). 
PL427 (N-(2-azidoethyl)-7-chloroquinolin-4-amine) 
PL30 (1 eq, 6.25 g, 20.8 mmol) was dissolved in dimethylformamide (65ml). Sodium 
azide (2 eq, 2.70 g, 41.6 mmol) was added, and the reaction mixture was stirred overnight 
at 55 
o
C. After completion, DI-water (85 ml) was added and the aqueous layer was 
extracted with toluene (3 * 250 ml). The organic layer was dried by anhydrous MgSO4, 
filtered and concentrated giving pure solid (5.02 g, 98 %). 
1
H NMR (400 MHz, 
Chloroform-d) δ 8.54 (d, J = 5.4 Hz, 4H), 8.01 (s, 5H), 7.96 (d, J = 2.2 Hz, 4H), 7.83 (d, J 
= 9.0 Hz, 4H), 7.34 (dd, J = 9.0, 2.2 Hz, 4H), 7.30 – 7.18 (m, 1H), 7.17 (dt, J = 7.9, 2.2 
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Hz, 1H), 6.42 (d, J = 5.3 Hz, 4H), 5.94 (t, J = 5.7 Hz, 4H), 3.66 (dd, J = 6.4, 5.0 Hz, 8H), 
3.53 (q, J = 5.6 Hz, 9H), 2.95 (s, 14H), 2.88 (s, 14H), 2.74 (s, 3H), 2.35 (s, 1H). 
General procedure for the synthesis of terminal alkynes: 
The 10 terminal alkynes PL428, PL429, PL430, PL431, PL432, PL433, PL434, PL435, 
PL436 and PL437 were prepared according to the following procedure: 
To a mixture of N-substituted piperazine (1 eq, 3.2 mmol) and anhydrous K2CO3 (1 eq, 
0.44 g, 3.2 mmol) in anhydrous acetonitrile (5 mL), propargyl bromide (80% W/V 
solution in toluene, 1 eq , 0.36 ml, 3.2 mmol) was added. The mixture was stirred 
overnight under reflux, and then filtered and evaporated. The residue was purified by 
combiflash chromatography using silica column eluting by Hexanes:EtOAc mixture. 
PL428 (2-(4-(prop-2-yn-1-yl)piperazin-1-yl)pyrimidine) 
0.21 g, 32 %. 
1
H NMR (400 MHz, DMSO-d6) δ 8.47 (dd, J = 11.1, 2 Hz, 11H), 6.79 (dt, 
J = 14.5, 4.9 Hz, 1H), 4.68 (s, 2H), 4.17 (s, 1H), 4.14 (dd, J = 13.0, 8.0 Hz, 4H), 3.67 (t, J 
= 5.1 Hz, 4H). 
PL429 (1-(prop-2-yn-1-yl)-4-(4-(trifluoromethyl)benzyl)piperazine) 
0.78 g, 87 %. 
1
H NMR (400 MHz, Chloroform-d) δ 7.56 (dd, 2H), 7.47 (dd, J = 11.2, 8.0 
Hz, 2H), 3.96 (t, J = 5.1 Hz, 2H), 3.56 (d, J = 18.7 Hz, 2H), 3.30 (d, J = 2.5 Hz, 2H), 3.09 
– 2.93 (m, 2H), 2.68 – 2.58 (m, 4H), 2.26 (t, J = 2.4 Hz, 1H). 
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PL430 (1-(prop-2-yn-1-yl)-4-(p-tolyl)piperazine) 
0.68 g, 99 %. 
1
H NMR (400 MHz, Chloroform-d) δ 7.14 – 7.02 (m, 2H), 6.93 – 6.74 (m, 
2H), 3.45 – 3.23 (m, 2H), 3.22 – 3.10 (m, 4H), 2.78 – 2.70 (m, 4H), 2.27 (d, J = 6.0 Hz, 
3H). 
PL431 (1-(prop-2-yn-1-yl)-4-(pyridin-2-yl)piperazine) 
0.45 g, 70 %. 
1
H NMR (400 MHz, Chloroform-d) δ 8.19 (tt, J = 4.9, 2.1 Hz, 1H), 7.63 – 
7.43 (m, 1H), 6.86 – 6.59 (m, 2H), 4.12 – 3.95 (m, 2H), 3.90 (t, J = 5.2 Hz, 2H), 3.71 – 
3.44 (m, 2H), 3.36 (d, J = 2.5 Hz, 2H),  2.73 – 2.65 (m, 2H), 2.28 (t, J = 2.5 Hz, 1H). 
PL432 (1-(4-(oxo-λ6-methyl)phenyl)-4-(prop-2-yn-1-yl)piperazine) 
1-(4-methoxyphenyl)-piperazine dihydrochloride (1 eq, 2 g, 7.5 mmol) was dissolved in 
water (20ml), and solid NaHCO3 (2.3 eq, 1.4 g, 17.1 mmol) was added with stirring. 
After addition of dichloromethane (25 ml), the aqueous phase was extracted with DCM 
(3 * 25ml) and the organic phase was dried by anhydrous MgSO4, filtered and 
concentrated by rotovap to give the free base starting material. 
0.7 g, 95 %. 
1
H NMR (400 MHz, Chloroform-d) δ 7.02 – 6.78 (m, 4H), 3.76 (d, J = 2.5 
Hz, 3H), 3.36 (d, J = 2.5 Hz, 2H), 3.17 – 2.98 (m, 4H), 2.78 – 2.55 (m, 4H), 2.28 (t, J = 
2.4 Hz, 1H). 
 
 
 96 
 
PL433 (1-phenyl-4-(prop-2-yn-1-yl)piperazine) 
0.56 g, 88 %. 
1
H NMR (400 MHz, Chloroform-d) δ 7.33 – 7.20 (m, 2H), 6.98 – 6.80 (m, 
3H), 3.36 (d, J = 2.5 Hz, 2H), 3.27 – 3.20 (m, 4H), 2.77 – 2.70 (m, 4H), 2.28 (t, J = 2.4 
Hz, 1H). 
PL434 (4-(4-(prop-2-yn-1-yl)piperazin-1-yl)phenol) 
0.39 g, 57 %. 
1
H NMR (400 MHz, DMSO-d6) δ 6.91 – 6.59 (m, 4H), 4.62 (d, J = 2.6 Hz, 
2H), 4.15 (t, 1H), 3.68 (t, J = 5.0 Hz, 2H), 3.39 (t, J = 4.8 Hz, 2H), 3.17 (s, 1H), 3.13 – 
3.01 (m, 4H). 
PL435 (1-(4-chlorophenyl)-4-(prop-2-yn-1-yl)piperazine) 
0.5 g, 67 %. 
1
H NMR (400 MHz, Chloroform-d) δ 7.27 – 7.15 (m, 2H), 6.91 – 6.78 (m, 
2H), 3.37 (d, J = 2.4 Hz, 2H), 3.26 – 3.16 (m, 4H), 2.78 – 2.69 (m, 4H), 2.28 (t, J = 2.5 
Hz, 1H). 
PL436 (1-cyclohexyl-4-(prop-2-yn-1-yl)piperazine) 
0.57 g, 86 %. 
1
H NMR (400 MHz, Chloroform-d) δ 3.34 (d, J = 2.5 Hz, 2H), 3.10 (dtd, 
4H), 2.42 – 2.26 (m, 3H), 1.95 (m, 2H), 1.53 (qd, J = 12.1, 3.4 Hz, 4H), 1.27 (m, 6H). 
PL437 (1-(3,4-dichlorophenyl)-4-(prop-2-yn-1-yl)piperazine) 
0.81 g, 94 %. 
1
H NMR (400 MHz, Chloroform-d) δ 7.39 – 7.22 (m, 1H), 7.01 – 6.84 (m, 
1H), 6.74 (ddd, J = 8.9, 4.9, 2.9 Hz, 1H), 3.41 – 3.29 (m, 2H), 3.25 – 3.10 (m, 4H), 2.80 – 
2.68 (m, 4H), 2.29 (t, J = 2.4 Hz, 1H). 
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PL439 (N
1
,N
3
-bis(7-chloroquinolin-4-yl)propane-1,3-diamine) 
To PL426 (1.5 eq, 0.88 g, 3.57 mmol) dissolved in acetonitrile (30ml), PL29 (1 eq, 0.75 
g, 2.38 mmol) and cesium carbonate (2 eq, 1.55 g, 4.76 mmol) was added. The reaction 
mixture was refluxed for 3 days. The solvent was evaporated and the crude was slurred in 
water (80 ml) in a sonicator for 30 minutes. The solid was filtered by vaccum-filtration 
and purified on silica column using combi-flash chromatography eluting by 
EtOAC:MeOH.  One of the peaks (collection 3) was collected and concentrated to give a 
yellow solid (0.1 g, 67 %). 
1
H NMR (400 MHz, Chloroform-d) δ 8.74 (d, J = 5.2 Hz, 
1H), 8.58 – 8.43 (m, 1H), 8.12 (d, J = 8.9 Hz, 1H), 8.05 (d, J = 2.0 Hz, 1H), 8.01 – 7.91 
(m, 1H), 7.66 (d, J = 9.0 Hz, 1H), 7.45 (dd, J = 8.9, 2.1 Hz, 1H), 7.40 – 7.26 (m, 1H), 
6.73 (d, J = 5.3 Hz, 1H), 6.49 (d, J = 5.4 Hz, 1H), 5.43 (s, 1H), 4.38 (t, J = 5.6 Hz, 2H), 
3.69 (q, J = 6.3 Hz, 2H), 2.43 (p, J = 6.3 Hz, 2H). m/z 397.08 M + H (calculated 397.30). 
General procedure for the synthesis of piperazine-linked triazoles: 
The 9 compounds PL440, PL441, PL442, PL443, PL444, PL445, PL446, PL447 and 
PL448 were prepared according to the following procedure: 
To a stirred solution of PL409 (1 eq, 0.25 g, 0.95 mmol) and synthesized N-piperazinyl-
substituted terminal alkynes (1.05 eq, 1.0 mmol) in tert-butanol (6.8 ml), CuSO4. 5H2O 
(0.1 eq, 0.024 g, 0.095 mmol) and sodium ascorbate (0.2 eq, 0.038 g, 0.19 mmol) in 
water (2.3 ml) was added. The mixture was stirred for 48 hours at 50 
o
C. After 
completion, the mixture of solvents was evaporated and the solid was purified using 
combi-flash chromatography in silica column by eluting using CHCl3:MeOH (90:10). 
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PL440 (7-chloro-N-(3-(4-((4-(pyrimidin-2-yl)piperazin-1-yl)methyl)-1H-1,2,3-
triazol-1-yl)propyl)quinolin-4-amine) 
0.32 g, 70 %. 
1
H NMR (400 MHz, DMSO-d6) δ 8.39 (d, J = 5.4 Hz, 1H), 8.34 (d, J = 4.8 
Hz, 2H), 8.26 (d, J = 9.0 Hz, 1H), 8.07 (s, 1H), 7.79 (d, J = 2.3 Hz, 1H), 7.47 (dd, J = 9.0, 
2.0 Hz, 1H), 7.35 (t, J = 5.4 Hz, 1H), 6.61 (t, J = 4.8 Hz, 1H), 6.42 (d, J = 5.4 Hz, 1H), 
4.49 (t, J = 6.9 Hz, 2H), 3.69 (t, J = 5.0 Hz, 4H), 3.60 (s, 2H), 3.28 (q, J = 6.5 Hz, 2H), 
2.44 (t, J = 5.0 Hz, 4H), 2.24 (h, J = 7.4, 7.0 Hz, 2H). 
13
C NMR (101 MHz, DMSO-d6) δ 
157.1, 141.3, 136.2, 129.7, 123.9, 110.1, 52.0, 47.2, 43.4, 38.9, 28.2 (d, J = 20.9 Hz). m/z 
463.20 M + H (calculated 463.97). 
PL441 (7-chloro-N-(3-(4-((4-(4-(trifluoromethyl)benzyl)piperazin-1-yl)methyl)-1H-
1,2,3-triazol-1-yl)propyl)quinolin-4-amine) 
0.16 g, 52 %. 
1
H NMR (400 MHz, DMSO-d6) δ 8.39 (d, J = 5.4 Hz, 1H), 8.26 (d, J = 9.0 
Hz, 1H), 8.01 (s, 1H), 7.79 (d, J = 2.3 Hz, 1H), 7.66 (d, J = 8.0 Hz, 2H), 7.50 (d, J = 8.0 
Hz, 2H), 7.47 (dd, J = 9.0, 2.0 Hz, 1H), 7.36 (t, J = 5.3 Hz, 1H), 6.41 (d, J = 5.5 Hz, 1H), 
4.49 (t, J = 6.9 Hz, 2H), 3.54 (d, J = 5.2 Hz, 4H), 3.27 (q, J = 6.5 Hz, 2H), 2.36 (s, 8H), 
2.22 (p, J = 6.9 Hz, 2H). 
13
C NMR (101 MHz, DMSO-d6) δ 151.7, 150.0, 148.8, 143.2, 
133.5, 129.3, 127.3, 125.0, 124.2, 124.0, 123.9, 120.9, 117.4, 98.7, 61.2, 52.4, 52.1, 47.2, 
28.4. m/z 543.22 M + H (calculated 544.02). 
PL442 (7-chloro-N-(3-(4-((4-(p-tolyl)piperazin-1-yl)methyl)-1H-1,2,3-triazol-1-
yl)propyl)quinolin-4-amine) 
0.17 g, 35 %. 
1
H NMR (400 MHz, DMSO-d6) δ 8.40 (d, J = 5.4 Hz, 1H), 8.26 (d, J = 9.0 
Hz, 1H), 8.06 (s, 1H), 7.80 (s, J = 2.3 Hz, 1H), 7.47 (dd, J = 9.0, 2.0 Hz, 1H), 7.37 (t, J = 
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5.2 Hz, 1H), 7.00 (d, J = 8.3 Hz, 2H), 6.84 – 6.76 (m, 2H), 6.42 (t, J = 6.4 Hz, 1H), 4.49 
(q, J = 6.8 Hz, 2H), 3.60 (s, 2H), 3.27 (s, 2H), 3.06 – 2.99 (m, 4H), 2.50 (d, J = 1.8 Hz, 
4H), 2.38 (d, J = 13.8 Hz, 2H), 2.32 – 2.16 (m, 3H). 13C NMR (101 MHz, DMSO-d6) δ 
151.0, 150.0, 133.5, 128.9, 124.2, 118.8, 115.3, 52.2, 48.1, 47.3, 28.4. m/z 475.23 M + H 
(calculated 476.03). 
PL443 (7-chloro-N-(3-(4-((4-(pyridin-2-yl)piperazin-1-yl)methyl)-1H-1,2,3-triazol-1-
yl)propyl)quinolin-4-amine) 
0.28 g, 61 %. 
1
H NMR (400 MHz, DMSO-d6) δ 8.43 – 8.37 (m, 1H), 8.27 (d, J = 9.0 Hz, 
1H), 8.17 – 8.05 (m, 2H), 7.80 (d, J = 2.3 Hz, 1H), 7.56 – 7.39 (m, 3H), 6.79 (d, J = 8.6 
Hz, 1H), 6.62 (dd, J = 7.0, 4.9 Hz, 1H), 6.44 (d, J = 5.5 Hz, 1H), 4.50 (t, J = 6.9 Hz, 2H), 
3.60 (s, 2H), 3.44 (t, J = 4.9 Hz, 4H), 3.29 (s, 2H), 2.47 (d, J = 5.0 Hz, 4H), 2.23 (p, J = 
6.9 Hz, 2H). 
13
C NMR (101 MHz, DMSO-d6) δ 147.5, 137.5, 124.3, 113.0, 107.1, 47.3, 
40.1, 38.8, 28.3. m/z 462.21 M + H (calculated 462.99). 
PL444 (7-chloro-N-(3-(4-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)-1H-1,2,3-
triazol-1-yl)propyl)quinolin-4-amine) 
0.37 g, 76 %. 
1
H NMR (400 MHz, DMSO-d6) δ 8.41 (s, 1H), 8.29 (d, J = 9.1 Hz, 1H), 
8.06 (s, 1H), 7.80 (d, J = 2.3 Hz, 1H), 7.55 – 7.46 (m, 2H), 6.90 – 6.75 (m, 4H), 6.46 (d, J 
= 5.4 Hz, 1H), 4.50 (t, J = 6.8 Hz, 2H), 3.68 (d, J = 9.3 Hz, 3H), 3.60 (s, 2H), 3.24 – 3.15 
(m, 2H), 2.97 (t, J = 4.9 Hz, 4H), 2.53 (d, J = 4.9 Hz, 4H), 2.24 (p, J = 6.9 Hz, 2H). 
13
C 
NMR (101 MHz, DMSO-d6) δ 124.3, 117.3, 114.2, 55.1, 38.8. m/z 491.22 M + H 
(calculated 492.02). 
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PL445 (7-chloro-N-(3-(4-((4-phenylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-
yl)propyl)quinolin-4-amine) 
0.32 g, 70 %. 
1
H NMR (400 MHz, DMSO-d6) δ 8.40 (d, J = 5.4 Hz, 1H), 8.34 – 8.23 (m, 
1H), 8.07 (s, 1H), 7.80 (d, J = 2.3 Hz, 1H), 7.47 (dd, J = 9.0, 2.2 Hz, 1H), 7.37 (t, J = 5.3 
Hz, 1H), 7.27 – 7.14 (m, 2H), 6.90 (d, J = 8.2 Hz, 2H), 6.76 (t, J = 7.2 Hz, 1H), 6.43 (d, J 
= 5.4 Hz, 1H), 4.51 (t, J = 6.9 Hz, 2H), 3.60 (s, 2H), 3.27 (d, J = 6.5 Hz, 2H), 3.08 (t, J = 
4.9 Hz, 4H), 2.52 (t, J = 4.9 Hz, 4H), 2.24 (p, J = 6.9 Hz, 2H). 
13
C NMR (101 MHz, 
DMSO-d6) δ 151.0, 150.0, 133.5, 128.9, 124.2, 118.8, 115.3, 52.2, 48.1, 47.3, 28.4. m/z 
461.21 M + H (calculated 462.00). 
PL446 (4-(4-((1-(3-((7-chloroquinolin-4-yl)amino)propyl)-1H-1,2,3-triazol-4-
yl)methyl)piperazin-1-yl)phenol) 
0.33 g, 68 %. 
1
H NMR (400 MHz, DMSO-d6) δ 8.79 (s, 1H), 8.42 – 8.23 (m, 3H), 8.06 
(d, J = 5.2 Hz, 1H), 7.79 (d, J = 2.3 Hz, 1H), 7.47 (dd, J = 9.0, 2.2 Hz, 1H), 7.36 (t, J = 
5.5 Hz, 1H), 6.84 – 6.70 (m, 1H), 6.67 – 6.57 (m, 1H), 6.42 (d, J = 5.4 Hz, 1H), 4.50 (td, 
J = 6.9, 2.1 Hz, 2H), 3.69 (t, J = 5.0 Hz, 2H), 3.59 (d, J = 3.8 Hz, 2H), 2.91 (t, J = 4.9 Hz, 
4H), 2.44 (t, J = 5.1 Hz, 2H), 2.23 (p, J = 6.9 Hz, 2H). 
13
C NMR (101 MHz, DMSO-d6) δ 
157.8, 149.8, 133.5, 124.12 (d, J = 11.1 Hz), 117.7, 115.4, 56.6, 52.4, 49.8, 47.3, 38.7, 
28.4. m/z 477.21 M + H (calculated 478.00). 
PL447 (7-chloro-N-(3-(4-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-1,2,3-
triazol-1-yl)propyl)quinolin-4-amine) 
0.40 g, 80 %. 
1
H NMR (400 MHz, DMSO-d6) δ 8.80 (s, 1H), 8.42 – 8.36 (m, 3H), 8.27 
(d, J = 9.1 Hz, 3H), 8.06 (d, J = 2.2 Hz, 3H), 7.79 (d, J = 2.3 Hz, 3H), 7.47 (dd, J = 9.0, 
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2.2 Hz, 4H), 7.36 (t, J = 5.1 Hz, 4H), 7.28 – 7.17 (m, 4H), 7.00 – 6.87 (m, 4H), 6.79 – 
6.70 (m, 2H), 6.67 – 6.58 (m, 2H), 6.42 (d, J = 5.4 Hz, 3H), 5.78 – 5.73 (m, 1H), 4.50 (t, 
J = 6.9 Hz, 2H), 3.59 (d, J = 3.7 Hz, 2H), 3.26 (s, 2H), 3.08 (t, J = 5.0 Hz, 4H), 2.91 (dd, J 
= 9.5, 4.5 Hz, 2H), 2.52 (s, 2H), 2.24 (h, J = 6.7 Hz, 2H). 
13
C NMR (101 MHz, DMSO-
d6) δ 150.2, 149.7, 133.7, 128.5, 127.5, 127.1, 124.2 (d, J = 8.4 Hz), 123.9, 122.3, 116.8, 
52.4, 52.0, 47.9, 47.3, 38.8, 28.4. m/z 495.17 M + H (calculated 496.44). 
PL448 (7-chloro-N-(3-(4-((4-(3,4-dichlorophenyl)piperazin-1-yl)methyl)-1H-1,2,3-
triazol-1-yl)propyl)quinolin-4-amine) 
0.41 g, 77 %. 
1
H NMR (400 MHz, DMSO-d6) δ 8.40 (s, 1H), 8.27 (d, J = 9.0 Hz, 1H), 
8.06 (s, 1H), 7.79 (d, J = 2.3 Hz, 1H), 7.51 – 7.34 (m, 3H), 7.10 (d, J = 2.9 Hz, 1H), 7.00 
– 6.87 (m, 1H), 6.43 (d, J = 5.4 Hz, 1H), 4.50 (t, J = 6.9 Hz, 2H), 3.56 (d, J = 26.0 Hz, 
2H), 3.32 – 3.24 (m, 2H), 3.13 (t, J = 5.0 Hz, 4H), 2.56 (s, 4H), 2.24 (h, J = 6.6 Hz, 2H). 
13
C NMR (101 MHz, DMSO-d6) δ 156.2, 152.2, 150.3, 133.5, 128.0, 127.2, 126.1, 
125.7, 124.1, 123.9, 109.4, 52.0, 51.7, 47.3, 38.9, 28.3. m/z 530.14 M + H (calculated 
530.88). 
PL456 (7-chloro-N-(3-(4-((4-(7-chloroquinolin-4-yl)piperazin-1-yl)methyl)-1H-1,2,3-
triazol-1-yl)propyl)quinolin-4-amine) 
The purified PL467 (1.07 eq, 1.15 g, 4.02 mmol) and PL409 (1 eq, 0.99 g, 3.76 mmol) 
dissolved in tert-butanol (15 ml) were mixed with CuSO4. 5H2O (0.15 eq, 0.14 g, 0.56 
mmol) and sodium ascorbate (0.3 eq, 0.22 g, 1.13 mmol) in water (5 ml) for 24 hours at 
50 
o
C. After evaporating the solvent, the crude was purified using combi-flash 
chromatography on silica by eluting in CHCl3:MeOH (90:10) to give the target 
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compound (1.2 g, 57 %). 
1H NMR (400 MHz, CDCl3) δ 8.70 (d, J = 5.0 Hz, 1H), 8.47 (d, 
J = 5.3 Hz, 1H), 8.03 (d, J = 2.1 Hz, 1H), 7.94 (d, J = 2.2 Hz, 1H), 7.91 (d, J = 8.9 Hz 
1H), 7.75 (d, J = 9.0 Hz, 1H), 7.57 (s, 1H), 7.41 (dd, J = 9.0, 2.1 Hz, 1H), 7.40 (dd, J = 
9.0, 2.3 Hz, 1H), 6.80 (d, J = 5.0 Hz, 1H), 6.36 (d, J = 5.4 Hz, 1H), 5.87 (t, J = 5.5 Hz, 
1H), 4.57 (t, J = 6.2 Hz, 2H), 3.78 (s, 2H), 3.47 (d, 2H), 3.20 (t, 4H), 2.77 (t, 4H), 2.39 (p, 
J = 6.5 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ 156.8, 151.8, 150.9, 150.1, 149.8, 
144.8, 135.5, 134.9, 128.8, 126.2, 125.8, 125.1, 123.6, 123.2, 121.9, 121.5, 108.9, 98.6, 
53.2, 52.8, 51.9, 48.1, 40.3, 28.3. m/z 547.19 M + H (calculated 547.49). 
PL457 (7-chloro-4-isothiocyanatoquinoline) 
A mixture of 4,7-dichloroquinoline (1 eq, 1.8 g, 9.09 mmol) and silverthiocyanate (2 eq, 
3.02 g, 18.18 mmol) was stirred in anhydrous toluene (15 ml) for 12 hours. The reaction 
was carried in disposable screw cap culture tube (100 ml) using fishr PTFE disposable 
bar stirrer. The hot mixture was filtered and the filtrate was washed with chloroform (3 * 
37.5 ml) and concentrated by rotovap to give a yellow solid (1.88 g , 94 %). 
1
H NMR 
(400 MHz, Chloroform-d) δ 8.86 (d, J = 4.7 Hz, 1H), 8.12 (d, J = 2.0 Hz, 1H), 8.03 (d, J 
= 8.9 Hz, 1H), 7.58 (dd, J = 8.9, 2.1 Hz, 1H), 7.26 (d, J = 4.7 Hz, 1H). 
PL459 (Methyl (3-((7-chloroquinolin-4-yl)amino)propyl)carbamodithioate) 
The intermediate product was synthesized in one-pot reaction by dissolving PL107 (1 eq, 
2.0 , 8.49 mmol) in dimethylsulfoxide (4 ml) and stirring at room temperature. Carbon 
disulfide (1.25 eq, 0.64 ml, 10.61 mmol) and 10 % NaOH (1.25 eq, 3.78 ml, 10.61 mmol) 
were added dropwise over 30 minutes. Then the mixture was stirred for another 30 
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minutes. After 1 hour, dimethylsulfate (1 eq, 0.81 ml, 8.49 mmol) was added at 5-10 
o
C, 
and the stirring continued for 3 hours. The sticky-brownish suspension formed was added 
to ice-water (50 ml)  and transferred to sep-funnel. The aqueous layer was extracted by 
chloroform (3 * 20 ml). The organic layer was washed by saturated NaHCO3 (25 ml) and 
then salted out by brine (20 ml). Finally the organic layer was dried by anhydrous 
MgSO4, filtered and concentrated to give brownish solid (0.8 g, 30 %). 
1
H NMR (400 
MHz, DMSO-d6) δ 9.99 (t, J = 5.2 Hz, 1H), 8.40 (d, J = 5.4 Hz, 1H), 8.25 (d, J = 9.0 Hz, 
1H), 7.80 (d, J = 2.3 Hz, 1H), 7.52 – 7.27 (m, 2H), 6.49 (t, J = 6.0 Hz, 1H), 3.66 (dtd, J = 
43.9, 6.9, 4.3 Hz, 2H), 3.32 (q, J = 6.6 Hz, 2H), 2.52 (d, J = 2.4 Hz, 3H), 1.99 (m, 2H). 
PL460 (Ethyl 4-((5H-cyclopenta[2,1-b:3,4-b']dipyridin-5-ylidene)amino)piperidine-
1-carboxylate) 
1,8-Diazafluoren-9-one (1 eq, 0.5 g, 2.74 mmol) and Ethyl-4-amino-1-piperidine 
carboxylate (1.15 eq, 0.54 ml, 3.15 mmol) was dissolved in anhydrous toluene (15 ml). 
Catalytic amount of p-toluene-sulfonic acid was added and the reaction was performed 
using dean-stark apparatus to remove the water continuously forming as a by-product. 
The reaction was refluxed stirring for 3 days. After the mixture was cooled to RT, the 
solvent was evaporated, and the crude was used in the next reaction prior to purification 
(0.88 g, 96 %). 
1
H NMR (400 MHz, DMSO-d6) δ 8.75 (ddd, J = 8.6, 4.9, 1.5 Hz, 2H), 
8.42 (dd, J = 8.0, 1.5 Hz, 1H), 8.12 (dd, J = 7.7, 1.6 Hz, 1H), 7.49 (ddd, J = 20.5, 7.7, 4.9 
Hz, 2H), 4.70 (tt, J = 9.1, 4.1 Hz, 1H), 4.09 (q, J = 7.1 Hz, 2H), 3.99 (ddd, J = 16.4, 7.8, 
4.1 Hz, 2H), 3.27 (s, 2H), 1.91 (dq, J = 12.3, 3.7 Hz, 2H), 1.80 – 1.62 (m, 2H), 1.20 (dt, J 
= 16.9, 7.1 Hz, 3H). 
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PL467 (7-chloro-4-(4-(prop-2-yn-1-yl)piperazin-1-yl)quinoline) 
PL49 (1 eq, 2.5 g, 10.1 mmol), propargyl bromide in 80 % W/V toluene (1 eq, 0.96 ml, 
10.1 mmol) and K2CO3 (1 eq, 1.4 g, 10.1 mmol) in acetonitrile (15 ml) were refluxed for 
48 hours. After the completion of the reaction was confirmed by TCL on alumina plate 
using EtOAC:MeOH (90:10) as eluents, the solvent was evaporated by rotovap. The 
crude was taken up by dichloromethane (40 ml) and washed by saturated NaHCO3 (3 * 
20 ml). All the aqueous phase were mixed and and extracted by DCM (30 ml). The two 
organic phases were mixed and dried by anhydrous MgSO4, filtered and concentrated. 
The crude was purified using combi-flash chromatography on silica using 
Hexanes:EtOAC as eluents give brownish solid (2.41 g, 83 %). 
1
H NMR (400 MHz, 
CDCl3) δ 8.71 (d, J = 5.0 Hz, 1H), 8.03 (d, J = 2.1 Hz, 1H), 7.94 (d, J = 8.9 Hz, 1H), 7.41 
(dd, J = 9.0, 2.1 Hz, 1H), 6.83 (d, J = 5.0 Hz, 1H), 3.44 (d, 2H), 3.27 (t, 4H), 2.86 (t, 4H), 
2.35 (t, 1H). 
7.3. In Vitro Drug Susceptibility Assays 
Both CQS (D6) and CQR (Dd2 and 7G8) P. falciparum maintained continuously in 
culture were used. Asynchronous cultures were diluted with uninfected RBCs and 
complete medium (RPMI-1640 with 0.5% Albumax II) to achieve 0.2% parasitemia and 
2% hematocrit. In 96-well microplates, CQ (positive control) or click compounds diluted 
in complete medium from 10 mM stock in DMSO were added to the cell mixture to yield 
triplicate wells with drug concentrations ranging from 0 to 10
-4
 M in a final well volume 
of 100 μL. After 72 h of incubation under standard culture conditions, plates were 
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harvested and read by the SYBR Green I fluorescence-based method using a 96-well 
fluorescence plate reader (Gemini-EM, Molecular Devices), with excitation and emission 
wavelengths at 497 and 520 nm, respectively. The fluorescence readings were plotted 
against log[drug], and the IC50 values were obtained from curve fitting performed by 
nonlinear regression using either Prism (GraphPad) or Excel (Microsoft) software. The 
values obtained for each cell line are normalized to CQ values of 5.9 nM for D6, 54 nM 
for Dd2, and 57 nM for 7G8. Errors were estimated to be ± 30%. This was determined by 
looking at the variability in IC50 values of 4 compounds, each with 3 or 4 sets of results 
per IC50 determination, and by taking into account the estimated uncertainties resulting 
from the weighing of the compounds. 
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APPENDICES 
      Appendix A: List of Intermediate Compounds Synthesized 
PL No. Structure PL No. Structure 
PL16 
 
PL28 
 
PL29 
 
PL30 
 
PL49 
 
PL107 
 
PL190 
 
PL46 
 
PL294 
 
PL323 
 
PL326 
 
PL334 
 
PL409 
 
PL422 
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PL424 
 
PL426 
 
PL427 
 
PL428 
 
PL429 
 
PL430 
 
PL431 
 
PL432 
 
PL433 
 
PL434 
 
PL435 
 
PL436 
 
PL437 
 
PL457 
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PL458 
 
PL459 
 
PL460 
 
PL467 
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Appendix B: List of Target Compounds Synthesized 
 
PL 
No. 
 
 
Click Compound 
IC50 
(D6, 
Dd2, 
7G8) 
 
HBD/ 
HBA 
 
NRot 
 
CLogP 
 
Mol.Wt 
CQ 
 
5.9 
54 
57 
1/3 8 4.75 305.85 
369 
 
>250 
>250 
>250 
1/5 8 5.63 450.59 
370 
 
>250 
>250 
>250 
1/4 8 6.37 436.60 
403 
 
10.4 
12.8 
14.5 
1/6 8 6.28 447.85 
404 
 
25 
81.6 
48 
2/6 8 4.84 469.97 
405 
 
98.6 
210 
192 
1/6 7 4.61 393.88 
 122 
 
406 
 
52.4 
120 
122 
1/6 7 5.17 393.88 
407 
 
81.0 
109 
129 
1/5 6 5.37 381.84 
408 
 
22.7 
39.1 
95.7 
1/5 6 5.44 399.83 
410 
 
9.6 
<2.5 
<2.5 
1/4 12 8.97 528.02 
411 
 
76.8 
87.5 
151 
1/5 6 5.19 363.85 
412 
 
423 
696 
592 
1/6 6 4.07 364.84 
 123 
 
413 
 
40.5 
61.4 
60 
1/5 6 5.69 377.88 
414 
 
9.6 
77.7 
85.8 
1/5 7 4.93 377.88 
415 
 
76.8 
345 
238 
2/6 6 4.05 378.86 
416 
 
423 
30.7 
49.6 
1/5 6 6.09 442.75 
417 
 
40.5 
109 
140 
1/6 8 5.17 393.88 
418 
 
18.8 
42.7 
36.6 
1/5 6 5.94 398.29 
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419 
 
11 
31.6 
18.7 
1/5 7 6.13 431.85 
420 
 
39.6 
85.2 
80.3 
1/5 6 5.37 381.84 
421 
 
18.8 
50.5 
44.5 
1/8 7 5.01 408.85 
423 
 
80.3 
160 
189 
2/6 10 4.96 483.02 
425 
 
20.5 
32.5 
86 
1/6 6 4.08 483.02 
439 
 
2.5 
4 
2.5 
2/4 6 6.87 397.30 
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440 
 
67 
>250 
>250 
1/9 8 3.11 463.97 
441 
 
10 
40 
16 
1/7 10 6.00 544.02 
442 
 
12 
37 
18 
1/7 8 5.33 476.03 
443 
 
41 
>250 
>250 
1/8 8 3.88 462.99 
444 
 
33 
68 
65 
1/8 10 4.85 492.02 
445 
 
17 
67 
74 
1/7 8 4.83 462.00 
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446 
 
155 
94.4 
>250 
2/8 8 4.16 478.00 
447 
 
8.8 
26.5 
19 
1/7 8 5.71 496.44 
448 
 
6.8 
15.2 
11 
1/7 8 6.36 530.88 
456 
 
0.5 
10 
11 
1/8 8 6.04 547.49 
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Appendix C: Selected Spectral and Chromatography Data 
1
H-Proton spectroscopy, COSY, HSQC, HMBC, NOESY, 
13
C-Spectroscopy, mass 
spectroscopy and combiflash chromatography data of selected compounds: 
            
                  PL403                                                                  PL448 
    
                                   PL410                                                              PL456 
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Figure 1.1. 
1
H-proton spectrum of PL403 
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Figure 1.2. COSY spectrum of PL403 
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Figure 1.3. HSQC spectrum of PL403 
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Figure 1.4. HMBC spectrum of PL403 
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Figure 1.5. NOESY spectrum of PL403 
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Figure 1.6. 
13
C-spectrum of PL403 
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Figure 1.7. Mass spectrum of PL403 
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Figure 2.1. 
1
H-proton spectrum of PL410 
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Figure 2.2. COSY spectrum of PL410 
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Figure 2.3. HSQC spectrum of PL410 
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Figure 2.4. HMBC spectrum of PL410 
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Figure 2.5. NOESY spectrum of PL410 
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Figure 2.6. 
13
C-spectrum of PL410 
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Figure 2.7. Mass spectrum of PL410 
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Figure 2.8. Combiflash chomatography of PL410 
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Figure 3.1. 
1
H-proton spectrum of PL448 
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Figure 3.2. COSY spectrum of PL448 
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Figure 3.3. HSQC spectrum of PL448 
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Figure 3.4. HMBC spectrum of PL448 
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Figure 3.5. NOESY spectrum of PL448 
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Figure 3.6. 
13
C-Specrum of PL448 
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Figure 3.7. Mass spectrum of PL448 
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Figure 3.8. Combiflash chromatography of PL448 
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Figure 4.1. 
1
H-proton spectrum of PL456 
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Figure 4.2. COSY spectrum of PL456 
 
 
 
 
 153 
 
 
 
 
 
Figure 4.3. HSQC spectrum of PL456 
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Figure 4.4. HMBC spectrum of PL456 
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Figure 4.5. NOESY spectrum of PL456 
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Figure 4.6. 
13
C-Spectrum of PL456 
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Figure 4.7. Mass spectrum of PL456 
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Figure 4.8. Combiflash Chromatography of PL456 
 
